NN (NNBR) 10-Q 11 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 07, 2020
Document And Entity Information [Abstract]
Entity Registrant Name	NN INC
Entity Central Index Key	0000918541
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus (i.e. Q1,Q2,Q3,FY)	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		42,757,128
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Net sales	$ 199,745	$ 213,256
Cost of sales (exclusive of depreciation and amortization shown separately below)	152,241	162,187
Selling, general and administrative expense	24,824	28,125
Depreciation and amortization	23,184	23,425
Restructuring and integration expense, net	0	(12)
Goodwill impairment	239,699	0
Other operating (income) expense, net	5,129	(152)
Loss from operations	(245,332)	(317)
Interest expense	17,077	13,801
Loss on extinguishment of debt and write-off of debt issuance costs	0	2,699
Other (income) expense, net	1,120	729
Loss before benefit (provision) for income taxes and share of net income (loss) from joint venture	(263,529)	(17,546)
Benefit (provision) for income taxes	15,609	(2,241)
Share of net income (loss) from joint venture	(271)	269
Net income (loss)	(248,191)	(19,518)
Other comprehensive loss:
Foreign currency translation gain (loss)	(14,342)	1,321
Change in fair value of interest rate swap, net of tax	(11,209)	(3,856)
Less: reclassification adjustment for (gains) losses included in net income, net of tax	1,052	0
Other comprehensive income (loss)	(24,499)	(2,535)
Comprehensive income (loss)	$ (272,690)	$ (22,053)
Basic net income (loss) per common share:
Net loss per share (in dollars per shares)	$ (5.96)	$ (0.47)
Weighted average shares outstanding (in shares)	42,111	41,972
Diluted net income (loss) per common share:
Net loss per share (in dollars per share)	$ (5.96)	$ (0.47)
Weighted average shares outstanding (in shares)	42,111	41,972

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 79,214	$ 31,703
Accounts receivable, net	128,458	131,558
Inventories	118,919	118,722
Income tax receivable	17,310	5,973
Other current assets	19,081	15,024
Total current assets	362,982	302,980
Property, plant and equipment, net	350,369	374,513
Operating lease right-of-use assets	68,407	65,496
Goodwill	196,281	439,095
Intangible assets, net	317,918	329,260
Investment in joint venture	21,120	21,755
Other non-current assets	8,076	8,885
Total assets	1,325,153	1,541,984
Current liabilities:
Accounts payable	59,792	57,340
Accrued salaries, wages and benefits	32,138	30,428
Income tax payable	922	1,028
Current maturities of long-term debt	20,064	19,160
Current portion of operating lease liabilities	5,775	6,652
Other current liabilities	33,842	24,873
Total current liabilities	152,533	139,481
Deferred tax liabilities	78,307	85,799
Non-current income tax payable	0	1,272
Long-term debt, net of current portion	814,972	757,440
Operating lease liabilities, net of current portion	72,389	66,980
Other non-current liabilities	32,386	44,723
Total liabilities	1,150,587	1,095,695
Commitments and contingencies (Note 12)
Series B convertible preferred stock - $0.01 par value per share, 100 shares authorized, 100 and 100 shares issued and outstanding at December 31, 2019, and March 31, 2020	95,664	93,012
Common stock - $0.01 par value per share, 90,000 shares authorized, 42,313 and 42,757 shares issued and outstanding at December 31, 2019, and March 31, 2020, respectively	428	423
Additional paid-in capital	499,925	501,615
Warrants	1,076	1,076
Accumulated deficit	(353,474)	(105,283)
Accumulated other comprehensive loss	(69,053)	(44,554)
Total stockholders’ equity	78,902	353,277
Total liabilities, preferred stock, and stockholders’ equity	1,325,153	$ 1,541,984
Change in fair value of interest rate swap, net of tax of $3,390	$ 11,209

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets - Parenthetical - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	90,000,000	90,000,000
Common stock, shares issued (in shares)	42,757,000	42,313,000
Common stock, shares outstanding (in shares)	42,757,000	42,313,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	100,000	100,000
Preferred stock, shares issued (in shares)	100,000	100,000
Preferred stock, shares outstanding (in shares)	100,000	100,000

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Warrants	Retained Earnings	AOCI Attributable to Parent
Beginning balance (in shares) at Dec. 31, 2018		42,104,000
Beginning balance at Dec. 31, 2018	$ 419,271	$ 421	$ 508,655		$ (58,491)	$ (31,314)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Net loss	(19,518)				(19,518)
Dividends declared or accrued for common stock	(2,942)		(2,942)
Share-based compensation expense (in shares)		281,000
Share-based compensation expense	873	$ 3	870
Restricted shares and performance shares forgiven for taxes and forfeited (in shares)		(18,000)
Restricted shares forgiven for taxes and forfeited	(141)		(141)
Change in fair value of interest rate swap, net of tax of $3,390	(3,856)					(3,856)
Reclassification of interest rate swap settlement to income, net of tax of $68	0
Foreign currency translation gain (loss)	1,321					1,321
Ending balance (in shares) at Mar. 31, 2019		42,367,000
Ending balance at Mar. 31, 2019	395,026	$ 424	506,442		(77,991)	(33,849)
Beginning balance (in shares) at Dec. 31, 2019		42,313,000
Beginning balance at Dec. 31, 2019	353,277	$ 423	501,615	$ 1,076	(105,283)	(44,554)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Net loss	(248,191)				(248,191)
Dividends accrued for preferred stock	(2,951)		(2,951)
Share-based compensation expense (in shares)		452,000
Share-based compensation expense	1,296	$ 5	1,291
Restricted shares and performance shares forgiven for taxes and forfeited (in shares)		(8,000)
Restricted shares forgiven for taxes and forfeited	(30)		(30)
Change in fair value of interest rate swap, net of tax of $3,390	(11,209)					(11,209)
Reclassification of interest rate swap settlement to income, net of tax of $68	1,052					1,052
Foreign currency translation gain (loss)	(14,342)					(14,342)
Ending balance (in shares) at Mar. 31, 2020		42,757,000
Ending balance at Mar. 31, 2020	$ 78,902	$ 428	$ 499,925	$ 1,076	$ (353,474)	$ (69,053)

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Stockholders' Equity [Abstract]
Change in fair value of interest rate swap, tax	$ 3,390	$ 1,104
Reclassification of interest rate swap settlement, tax	$ (318)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities
Net loss	$ (248,191)	$ (19,518)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	23,184	23,425
Amortization of debt issuance costs	1,652	1,191
Goodwill impairment	239,699	0
Loss on extinguishment of debt and write-off of debt issuance costs	0	2,699
Share of net income/loss from joint venture, net of cash dividends received	271	(269)
Compensation expense from issuance of share-based awards	1,296	873
Deferred income taxes	(3,923)	(5,704)
Other	614	182
Changes in operating assets and liabilities:
Accounts receivable	1,760	(13,963)
Inventories	(2,507)	(5,625)
Accounts payable	3,584	7,236
Income taxes receivable and payable, net	(12,676)	1,579
Other	5,461	5,182
Net cash provided by (used in) operating activities	10,224	(2,712)
Cash flows from investing activities
Acquisition of property, plant and equipment	(11,260)	(14,073)
Proceeds from liquidation of short-term investment	0	(8,000)
Proceeds from sale of property, plant, and equipment	82	2,395
Other	0	(1)
Net cash provided by (used in) investing activities	(11,178)	(3,679)
Cash flows from financing activities
Cash paid for debt issuance or prepayment costs	(286)	(738)
Dividends paid	0	(2,947)
Proceeds from long-term debt	60,012	19,025
Repayment of long-term debt	(4,527)	(7,522)
Proceeds from (repayments of) short-term debt, net	(411)	1,982
Other	(888)	(924)
Net cash provided by (used in) financing activities	53,900	8,876
Effect of exchange rate changes on cash flows	(5,435)	(204)
Net change in cash and cash equivalents	47,511	2,281
Cash and cash equivalents at beginning of period	31,703	17,988
Cash and cash equivalents at end of period	$ 79,214	$ 20,269

Interim Financial Statements

Interim Financial Statements	3 Months Ended
	Mar. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Interim Financial Statements	Interim Financial Statements Nature of Business NN, Inc. is a global diversified industrial company that combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for the medical, aerospace and defense, electrical, automotive, and general industrial markets. As used in this Quarterly Report on Form 10-Q (this “Quarterly Report”), the terms “NN,” the “Company,” “we,” “our,” or “us” refer to NN, Inc., and its subsidiaries. Basis of Presentation and Going Concern The accompanying condensed consolidated financial statements have not been audited, except that the Condensed Consolidated Balance Sheet as of December 31, 2019 , was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the “ 2019 Annual Report”), which we filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 16, 2020 . In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary to fairly state our results of operations for the three months ended March 31, 2020 and 2019 ; financial position as of March 31, 2020 , and December 31, 2019 ; and cash flows for the three months ended March 31, 2020 and 2019 , on a basis consistent with our audited consolidated financial statements other than the adoption of new accounting standards (see Accounting Standards Recently Adopted section below). These adjustments are of a normal recurring nature and are, in the opinion of management, necessary to state fairly the Company’s financial position and operating results for the interim periods. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted from the interim financial statements presented in this Quarterly Report. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and accompanying notes included in the 2019 Annual Report. The results for the three months ended March 31, 2020 , are not necessarily indicative of results for the year ending December 31, 2020 , or any other future periods. Except for per share data or as otherwise indicated, all U.S. dollar amounts presented in the tables in these Notes to Condensed Consolidated Financial Statements are in thousands. In November 2019, we initiated a strategic review to evaluate a broad range of operational, financial, and strategic options to reduce leverage and enhance shareholder value, and we retained external advisors to assist in this effort. The strategic options we are evaluating include further cost savings and cash generation initiatives, more efficient capital deployment, changes to our debt and equity structure to improve financial flexibility and liquidity, and the sale of part or all of NN, among others. As discussed in our 2019 Annual Report, on December 11, 2019, we issued preferred stock for net proceeds of $95.7 million and used a portion of the proceeds to repay amounts due at that time on our Senior Secured Revolver. In December 2019 we amended our Credit Agreement which, in turn, extended the due date of our Senior Secured Revolver to July 20, 2022 , reduced the total capacity under the Senior Secured Revolver to $75.0 million , and extended the due date of our Incremental Term Loan to October 19, 2022 , matching the date of our longer-dated Senior Secured Term Loan. Additionally, as part of this amendment, our debt covenants were amended to establish more restrictive leverage ratios that also become more restrictive over time. Our Consolidated Net Leverage Ratio covenant (the “financial leverage ratio covenant”) is required to be complied with on a quarterly basis at the end of each of our quarterly reporting periods. Our financial leverage ratio covenant is based upon our consolidated net indebtedness at each quarter end and our trailing twelve-month Adjusted EBITDA as defined in our Credit Agreement. In order to maintain compliance with the financial leverage ratio covenant, our operational and financial performance must improve . In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued. We rely on cash flow generated from operations and available borrowings under our Senior Secured Revolver to fund our working capital and other operating and investing needs. Our ability to borrow under the Senior Secured Revolver is based on our continued compliance with our financial leverage ratio covenant, as defined, which becomes more restrictive in the second quarter of 2020 and the first quarter of 2021. The full extent of the effect of the COVID-19 pandemic on our customers, our supply chain and our business cannot be reasonably assessed at this time although we expect our full year 2020 results of operations to be adversely affected. We have developed a plan to mitigate the impact of COVID-19 which includes the implementation of a series of specific and identified cost reductions in both our corporate and business groups, in addition to actions already taken, including further reducing our direct and indirect labor costs and benefits. The impact of COVID-19 on our operating results will depend on future developments, which are highly uncertain and cannot be predicted, including governmental and business reactions to the pandemic. We have made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. If there are differences between these estimates and actual results, our consolidated financial statements may be materially affected. Based on our current and projected use of the Senior Secured Revolver, as well as cash flows expected to be generated from operations and investing activities, we anticipate that we may not be able to maintain compliance with the existing financial leverage ratio covenant for the next twelve months. If we are unable to comply with our financial ratio covenant, then the revolving credit lenders, the Senior Secured Term Loan lenders, and the Incremental Term Loan lenders could take action to cause amounts due under our credit facility to become due and payable unless we are able to amend such covenants or otherwise refinance our debt. Our ability to amend our covenants or refinance our debt is dependent upon several factors, and therefore there can be no assurance that we would be successful in these efforts. If we are unable to access future borrowings or be required to pay amounts due under our credit facilities prior to their normal maturity dates, this would have a material impact to our financial position. We are in negotiations with our lenders to amend the financial leverage ratio covenant; however, there can be no assurance that we will be successful in such efforts. Accordingly, we believe there is substantial doubt about our ability to continue as a going concern for the twelve-month period following the date of this report. Accounting Standards Recently Adopted Financial Instruments - Credit Losses . In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which modifies the measurement of expected credit losses on certain financial instruments and the timing of when such losses are recorded. In November 2019, the SEC issued SAB No. 119, codified in ASC Topic 326, Financial Instruments-Credit Losses, which provides guidance on accounting of credit losses. We adopted ASU 2016-13 on January 1, 2020, using the modified retrospective transition method which resulted in no material adjustment to our financial statements as of January 1, 2020. Fair Value Disclosures. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”) , that modifies fair value disclosure requirements. The new guidance streamlines disclosures of Level 3 fair value measurements. The modified disclosures were effective for us beginning in the first quarter of 2020. ASU 2018-13 changes disclosures only and does not impact our financial condition, results of operations, or cash flows. Internal-Use Software. In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force) (“ASU 2018-15”) , that provides guidance on a customer’s accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor. Under the new guidance, customers apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. We adopted ASU 2018-15 as of January 1, 2020, prospectively. We have had no such costs after the adoption date, and we do not expect the new guidance to have a material impact on our financial statements. Reference Rate Reform. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides temporary optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. Among other things, for all types of hedging relationships, the guidance allows an entity to change the reference rate and other critical terms related to reference rate reform without having to remeasure the value or reassess a previous accounting determination. The amendments in this guidance should be applied on a prospective basis and, for companies with a fiscal year ending December 31, are effective from January 1, 2020, through December 31, 2022. We adopted this guidance effective January 1, 2020. When the transition occurs, we expect to apply this expedient to our existing interest rate swap that references LIBOR, and to any other new transactions that reference LIBOR or another reference rate that is discontinued, through December 31, 2022. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements. Accounting Standards Not Yet Adopted Income Taxes. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, (“ASU 2019-12”) as part of its initiative to reduce complexity in accounting standards. ASU 2019-12 removes certain exceptions and provides simplification to specific tax items to improve consistent application. This standard is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued. Adoption methods vary based on the specific items impacted. We are currently evaluating the impact on our financial statements and related disclosures.

Prior Periods' Financial Statem

Prior Periods' Financial Statement Revision Prior Periods' Financial Statement Revision	3 Months Ended
	Mar. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Prior Periods' Financial Statement Revision	Prior Periods' Financial Statement Revisions As disclosed in our 2019 Annual Report, we identified various misstatements in our previously issued financial statements as of and for the years ended December 31, 2018 and 2017, as well as the interim periods in 2018 and the first three quarters of 2019. These misstatements primarily related to (i) intentional misstatements in the accounting for inventory at one of our smaller foreign subsidiaries and (ii) the tax accounting associated with the 2018 impairment of our joint venture. We assessed the materiality of the misstatements on prior periods’ financial statements in accordance with SEC Staff Accounting Bulletin (“SAB”) Topic 1.M, Materiality , codified in Accounting Standards Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections , (“ASC 250”) and concluded that the misstatements were not material to the prior annual or interim periods. However, we revised our previously issued 2018 and 2017 annual consolidated financial statements to correct for these misstatements. In connection with such revision, we also corrected for other immaterial misstatements. In connection with the filing of this Quarterly Report, we have revised the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), Changes in Stockholders’ Equity, and Cash Flows for the three months ended March 31, 2019 , and the related notes to revise for those misstatements that impacted such period. We will revise the remaining 2019 previously issued quarterly financial statements in connection with future 2020 filings on Form 10-Q. The following table presents the effect of the correction of the misstatements and the resulting revision on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) . Three Months Ended March 31, 2019 As Originally Reported Adjustment As Revised Cost of sales (exclusive of depreciation and amortization) $ 161,269 $ 918 $ 162,187 Income (loss) from operations 601 (918 ) (317 ) Loss before (provision) benefit for income taxes and share of net income from joint venture (16,628 ) (918 ) (17,546 ) Net income (loss) (18,600 ) (918 ) (19,518 ) Foreign currency translation gain (loss) 1,262 59 1,321 Comprehensive income (loss) (21,194 ) (859 ) (22,053 ) Basic net income (loss) per share $ (0.44 ) $ (0.03 ) $ (0.47 ) Diluted net income (loss) per share $ (0.44 ) $ (0.03 ) $ (0.47 ) The following table presents the effect of the correction of the misstatements on the Condensed Consolidated Statements of Changes in Stockholders’ Equity . As Originally Reported Adjustment As Revised As of and for the three months ended March 31, 2019 Additional paid-in capital $ 512,274 $ (5,832 ) $ 506,442 Net income (loss) (18,600 ) (918 ) (19,518 ) Accumulated deficit (83,570 ) 5,579 (77,991 ) Foreign currency translation gain (loss) 1,262 59 1,321 Accumulated other comprehensive income (loss) (34,219 ) 370 (33,849 ) Total stockholders' equity 394,909 117 395,026 The following table presents the effect of the correction of the misstatements on the Condensed Consolidated Statements of Cash Flows . Three Months Ended March 31, 2019 As Originally Reported Adjustment As Revised Net income (loss) $ (18,600 ) $ (918 ) $ (19,518 ) Deferred income taxes (4,373 ) (1,331 ) (5,704 ) Changes in operating assets and liabilities, net of acquisitions: Inventories (6,302 ) 677 (5,625 ) Income taxes receivable and payable, net 248 1,331 1,579 Other 4,941 241 5,182

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Information	Segment Information Management has concluded that Life Sciences, which is focused on growth in the medical end market, primarily in the orthopaedics and medical/surgical end markets; Mobile Solutions, which is focused on growth in the general industrial and automotive end markets; and Power Solutions, which is focused on growth in the electrical and aerospace and defense end markets, constitute our operating segments. Life Sciences, Mobile Solutions, and Power Solutions are considered operating segments as each engages in business activities for which it earns revenues and incurs expenses, discrete financial information is available for each, and this is the level at which the Chief Operating Decision Maker (“CODM”) reviews discrete financial information for purposes of allocating resources and assessing performance. The following tables present results of operations by reportable segment. Life Sciences Mobile Solutions Power Solutions Corporate and Consolidations Total Three Months Ended March 31, 2020 Net sales $ 84,048 $ 69,884 $ 46,401 $ (588 ) (a) $ 199,745 Goodwill impairment 146,757 — 92,942 — 239,699 Income (loss) from operations (140,979 ) 264 (90,334 ) (14,283 ) $ (245,332 ) Interest expense (17,077 ) Other (1,120 ) Loss before benefit for income taxes and share of net loss from joint venture $ (263,529 ) Three Months Ended March 31, 2019 Net sales $ 86,008 $ 78,075 $ 49,657 $ (484 ) (a) $ 213,256 Income (loss) from operations 3,846 3,189 3,824 (11,176 ) $ (317 ) Interest expense (13,801 ) Other (3,428 ) Loss before provision for income taxes and share of net income from joint venture $ (17,546 ) _______________________________ (a) Includes elimination of intersegment transactions occurring during the ordinary course of business. The following table presents total assets by reportable segment as of March 31, 2020 , and December 31, 2019 . Total Assets March 31, 2020 December 31, 2019 Life Sciences $ 648,603 $ 811,526 Mobile Solutions 362,624 373,256 Power Solutions 214,602 310,545 Corporate and Consolidations 99,324 46,657 Total $ 1,325,153 $ 1,541,984

Inventories

Inventories	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are comprised of the following amounts: March 31, 2020 December 31, 2019 Raw materials $ 36,904 $ 49,135 Work in process 47,054 43,456 Finished goods 34,961 26,131 Total inventories $ 118,919 $ 118,722

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The following table shows changes in the carrying amount of goodwill by reportable segment. Life Sciences Power Solutions Total Balance as of December 31, 2019 $ 344,316 $ 94,779 $ 439,095 Currency impact and other (1,278 ) (1,837 ) (3,115 ) Impairments (146,757 ) (92,942 ) (239,699 ) Balance as of March 31, 2020 $ 196,281 $ — $ 196,281 As of March 31, 2020 , and December 31, 2019 , no goodwill was recorded in the Mobile Solutions reportable segment. During the first quarter of 2020, our market capitalization declined to a level that was less than the net book value of our stockholders’ equity. The decline in market capitalization was a triggering event that caused us to perform a goodwill impairment analysis as of March 31, 2020. The goodwill impairment analysis required significant judgments to calculate the fair value for each of Life Sciences and Power Solutions, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term growth rate for each operating segment, and determination of weighted average cost of capital. Our forecasts used in the goodwill impairment analysis reflect our expectations of declines in sales resulting from COVID-19. Significant assumptions and estimates are involved in the application of the discounted cash flow model to forecast operating cash flows, including market growth and market share, sales volumes and prices, costs to produce, discount rate, and estimated capital needs. Management considers historical experience and all available information at the time the fair values of its reporting units are estimated. Assumptions in estimating future cash flows are subject to a high degree of judgment and complexity. Changes in assumptions and estimates may affect the fair value of goodwill and could result in impairment charges in future periods. Management’s judgment used in the assessment of fair value is more significant under the current market conditions and economic uncertainty created by COVID-19. The carrying values of the Life Sciences and Power Solutions reporting units exceeded their estimated fair values as of March 31, 2020. As a result of our analysis, we recorded an impairment loss on goodwill of $146.8 million and $92.9 million for Life Sciences and Power Solutions, respectively, to the “ Goodwill impairment ” line on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) . Life Sciences goodwill as of March 31, 2020 , was $196.3 million . In conjunction with the goodwill impairment test performed during the first quarter of 2020, Life Sciences goodwill was impaired by $146.8 million , resulting in the carrying value of the reporting unit being equal to its fair value. If our assessment of the relevant facts and circumstances change, or if the actual performance falls short of expected results, an additional impairment charge will be required. An impairment of goodwill may also lead us to record an impairment of other intangible assets. The carrying value of finite-lived intangible assets for the Life Sciences group as of March 31, 2020 , was $204.1 million .

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets, Net The following table shows changes in the carrying amount of intangible assets, net by reportable segment. Life Sciences Mobile Solutions Power Solutions Total Balance as of December 31, 2019 $ 211,847 $ 32,416 $ 84,997 $ 329,260 Amortization (7,755 ) (839 ) (2,748 ) (11,342 ) Balance as of March 31, 2020 $ 204,092 $ 31,577 $ 82,249 $ 317,918 Intangible assets are tested for impairment when changes in circumstances indicate the carrying value of those assets may not be recoverable. As of March 31, 2020 , the goodwill impairment testing trigger caused us to test intangible assets in all of our reportable segments for impairment as well. Based on our analysis, no impairment charge was deemed necessary in the three months ended March 31, 2020 .

Investment in Joint Venture

Investment in Joint Venture	3 Months Ended
	Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Investment in Joint Venture	Investment in Joint Venture We own a 49% investment in Wuxi Weifu Autocam Precision Machinery Company, Ltd. (the “JV”), a joint venture located in Wuxi, China. The JV is jointly controlled and managed, and we account for it under the equity method. The following table shows changes in our investment in the JV. Balance as of December 31, 2019 $ 21,755 Share of earnings (loss) (271 ) Foreign currency translation loss (364 ) Balance as of March 31, 2020 $ 21,120 During the fourth quarter of 2018, as a result of changing market conditions, the fair value of the JV was assessed, and we recorded an impairment of $16.6 million against our investment in the JV. The fair value assessment was significantly affected by changes in our assessment of future growth rates. During the first quarter of 2020 , the goodwill impairment testing trigger caused us to test the JV for impairment as well. Based on our analysis, no impairment charge was deemed necessary in the three months ended March 31, 2020 . It is reasonably possible that material deviation of future performance from the estimates used in the March 31, 2020, impairment test could result in additional impairment to our investment in the JV in subsequent periods. We recognized sales to the JV of less than $0.1 million and less than $0.1 million during the three months ended March 31, 2020 and 2019 , respectively.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted. Among other provisions, the CARES Act allows for the carryback of certain tax losses and favorably impacts the deductibility of interest expense and depreciation. The CARES Act had a material impact on our financial statements and has been accounted for in the benefit/provision for income taxes for the three months ended March 31, 2020 , which is the period of enactment. Our effective tax rate was 5.9% for the three months ended March 31, 2020 , and (12.8)% for the three months ended March 31, 2019 . The effective tax rate for the three months ended March 31, 2020 , differs from the U.S. federal statutory tax rate of 21% primarily due to the impact of the impairment of nondeductible goodwill which is treated as a permanent difference. The effective tax rate was also impacted by the CARES Act and the anticipated withholding taxes which would be due upon repatriation of the unremitted earnings of foreign subsidiaries. Our effective tax rate for the three months ended March 31, 2019 , differs from the U.S. federal statutory tax rate of 21% principally due to a discrete tax charge of $6.0 million related to final tax regulations published by the Department of the Treasury and Internal Revenue Service on February 4, 2019, as well as the minimum tax on global intangible low-tax income (“GILTI”).

Debt

Debt	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt	Debt Collectively, our credit facility is comprised of a term loan with a face amount of $545.0 million , maturing on October 19, 2022 (the “Senior Secured Term Loan”); a term loan with a face amount of $300.0 million , maturing on October 19, 2022 (the “Incremental Term Loan”); and a revolving line of credit with a face amount of $75.0 million , maturing on July 20, 2022 (the “Senior Secured Revolver”). The credit facility is collateralized by all of our assets. The following table presents debt balances as of March 31, 2020 , and December 31, 2019 . March 31, 2020 December 31, 2019 Senior Secured Term Loan $ 524,875 $ 526,313 Incremental Term Loan 254,222 257,111 Senior Secured Revolver 60,000 — International lines of credit and other loans 11,140 9,823 Total principal 850,237 793,247 Less-current maturities of long-term debt 20,064 19,160 Principal, net of current portion 830,173 774,087 Less-unamortized debt issuance costs (1) 15,201 16,647 Long-term debt, net of current portion $ 814,972 $ 757,440 _______________________________ (1) In addition to this amount, costs of $2.7 million and $3.0 million related to the Senior Secured Revolver are recorded in other non-current assets as of March 31, 2020 , and December 31, 2019 , respectively. We capitalized interest costs of $0.3 million and $0.6 million in the three months ended March 31, 2020 and 2019 , respectively, related to construction in progress. Senior Secured Term Loan Outstanding borrowings under the Senior Secured Term Loan bear interest at the greater of 0.75% or one-month LIBOR plus an applicable margin of 5.75% . At March 31, 2020 , the Senior Secured Term Loan bore interest at 6.74% . Incremental Term Loan Outstanding borrowings under the Incremental Term Loan bear interest at one-month LIBOR plus an applicable margin of 5.75% . At March 31, 2020 , the Incremental Term Loan bore interest of 6.74% . Senior Secured Revolver Outstanding borrowings under the Senior Secured Revolver bear interest on a variable rate structure with borrowings bearing interest at either one-month LIBOR plus an applicable margin of 4.00% or the prime lending rate plus an applicable margin of 3.00% . At March 31, 2020 , the weighted average interest rate on outstanding borrowings under the Senior Secured Revolver was 4.96% . We pay a commitment fee of 0.50% for unused capacity under the Senior Secured Revolver. We had $60.0 million outstanding under the Senior Secured Revolver at March 31, 2020 . Total capacity under the Senior Secured Revolver was $75.0 million as of March 31, 2020 , with $3.4 million available for future borrowings after reductions for outstanding letters of credit and outstanding borrowings as of March 31, 2020 . Our credit facility is subject to certain financial covenants based on a consolidated net leverage ratio, becoming more restrictive over time. If our operational or financial performance does not improve, we may be required to take actions to further reduce expenditures and decrease our net indebtedness to maintain compliance in future periods or attempt to amend our covenants or refinance our debt. We were in compliance with all covenants under our credit facility at March 31, 2020 . Derivative Instruments and Hedging Activities In February 2019, we entered into a $700.0 million amortizing notional amount fixed-rate interest rate swap agreement to manage the interest rate risk associated with our long-term variable-rate debt until 2022. The fixed-rate interest rate swap agreement calls for us to receive interest monthly at a variable rate equal to one-month LIBOR and to pay interest monthly at a fixed rate of 2.4575% . Refer to Note 18 for further discussion of the interest rate swap agreement.

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	Leases The following table contains supplemental cash flow information related to leases. Three Months Ended 2020 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from finance leases $ 120 $ 53 Operating cash flows from operating leases 5,346 5,288 Financing cash flows from finance leases 836 792 Right-of-use assets obtained in exchange for new finance lease liabilities $ 1,404 $ — Right-of-use assets obtained in exchange for new operating lease liabilities $ 13,241 $ 2,836 As disclosed in our 2019 Annual Report, we had an operating lease commitment that had not yet commenced. In March 2020, the operating lease for the manufacturing facility commenced and requires us to pay a total of approximately $27.5 million base rent payments over the lease term of 15 years . We will begin making rent payments in the third quarter of 2020. In March 2020, we amended the lease of our corporate headquarters building to exit over half of the previously leased space and reduce annual base rent payments by approximately $1.3 million over the remaining lease term which ends in 2030. The amendment was accounted for as a lease modification, and the remeasurement of the lease resulted in an $8.1 million decrease in the operating lease right-of-use (“ROU”) asset, a $10.5 million decrease in the noncurrent portion of the operating lease liability, and a $0.6 million decrease in the current portion of the operating lease liability. The $3.0 million difference between the change in the operating lease ROU asset and the operating lease liabilities was recognized in “ Other operating (income) expense, net ,” on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) . In connection with the discontinued use of the previously leased space, we also recognized a $4.4 million termination charge and a $2.9 million impairment charge on the associated leasehold improvements, all of which were also recognized in “ Other operating (income) expense, net .”
Leases	Leases The following table contains supplemental cash flow information related to leases. Three Months Ended 2020 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from finance leases $ 120 $ 53 Operating cash flows from operating leases 5,346 5,288 Financing cash flows from finance leases 836 792 Right-of-use assets obtained in exchange for new finance lease liabilities $ 1,404 $ — Right-of-use assets obtained in exchange for new operating lease liabilities $ 13,241 $ 2,836 As disclosed in our 2019 Annual Report, we had an operating lease commitment that had not yet commenced. In March 2020, the operating lease for the manufacturing facility commenced and requires us to pay a total of approximately $27.5 million base rent payments over the lease term of 15 years . We will begin making rent payments in the third quarter of 2020. In March 2020, we amended the lease of our corporate headquarters building to exit over half of the previously leased space and reduce annual base rent payments by approximately $1.3 million over the remaining lease term which ends in 2030. The amendment was accounted for as a lease modification, and the remeasurement of the lease resulted in an $8.1 million decrease in the operating lease right-of-use (“ROU”) asset, a $10.5 million decrease in the noncurrent portion of the operating lease liability, and a $0.6 million decrease in the current portion of the operating lease liability. The $3.0 million difference between the change in the operating lease ROU asset and the operating lease liabilities was recognized in “ Other operating (income) expense, net ,” on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) . In connection with the discontinued use of the previously leased space, we also recognized a $4.4 million termination charge and a $2.9 million impairment charge on the associated leasehold improvements, all of which were also recognized in “ Other operating (income) expense, net .”

Restructuring and Integration

Restructuring and Integration	3 Months Ended
	Mar. 31, 2020
Restructuring and Related Activities [Abstract]
Restructuring and Integration	Restructuring and Integration We incurred no new restructuring and integration charges for the three months ended March 31, 2020 . During the three months ended March 31, 2020 , we made cash payments of $0.1 million for restructuring costs. As of March 31, 2020 , we had $0.4 million accrued for severance costs associated with restructuring and integration projects. We expect to pay this balance over the next 1.2 years. We expect to pay $0.3 million within the next twelve months.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Brazil ICMS Tax Matter Prior to the acquisition of Autocam Corporation in 2014 (“Autocam”), Autocam’s Brazilian subsidiary (“Autocam Brazil”) received notification from the Brazilian tax authority regarding ICMS (state value added tax or “VAT”) tax credits claimed on intermediary materials (e.g., tooling and perishable items) used in the manufacturing process. The Brazilian tax authority notification disallowed state ICMS tax credits claimed on intermediary materials based on the argument that these items are not intrinsically related to the manufacturing processes. Autocam Brazil filed an administrative defense with the Brazilian tax authority arguing, among other matters, that it should qualify for an ICMS tax credit, contending that the intermediary materials are directly related to the manufacturing process. We believe that we have substantial legal and factual defenses, and we plan to defend our interests in this matter vigorously. The matter encompasses several lawsuits filed with the Brazilian courts requesting declaratory actions that no tax is due or seeking a stay of execution on the collection of the tax. In 2018, we obtained a favorable decision in one of the declaratory actions for which the period for appeal has expired. We have filed actions in each court requesting dismissal of the matter based on the earlier court action. Although we anticipate a favorable resolution to all matters, we can provide no assurances that we will be successful in achieving dismissal of all pending cases. While we believe a loss is not probable, we estimate the range of possible losses related to this assessment is from $0 to $6.0 million . No amount was accrued at March 31, 2020 , for this matter. We are entitled to indemnification from the former shareholders of Autocam, subject to the limitations and procedures set forth in the agreement and plan of merger relating to the Autocam acquisition. Management believes the indemnification would include amounts owed for the tax, interest, and penalties related to this matter. Securities Offering Matter On November 1, 2019, Erie County Employees’ Retirement System, on behalf of a purported class of plaintiffs, filed a complaint in the Supreme Court of the State of New York, County of New York, against the Company, certain of the Company’s current and former officers and directors, and each of the underwriters involved in the Company’s public offering and sale of 14.4 million shares of its common stock pursuant to a preliminary prospectus supplement, dated September 10, 2018, a final prospectus supplement, dated September 13, 2018, and a base prospectus, dated April 19, 2017, relating to the Company’s effective shelf registration statement on Form S-3 (File No. 333-216737) (the “Offering”), which complaint was amended on January 24, 2020. The complaint alleges violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 in connection with the Offering. The plaintiffs seek to represent a class of stockholders who purchased shares of the Company’s common stock in the Offering. The complaint seeks unspecified monetary damages and other relief. The Company believes the complaint and allegations to be without merit and intends to vigorously defend itself against these actions. The Company is unable at this time to determine whether the outcome of the litigation would have a material impact on the Company’s financial position, results of operations, or cash flows. All Other Legal Matters All other legal proceedings are of an ordinary and routine nature and are incidental to our operations. Management believes that such proceedings should not, individually or in the aggregate, have a material adverse effect on our business, financial condition, results of operations, or cash flows. In making that determination, we analyze the facts and circumstances of each case at least quarterly in consultation with our attorneys and determine a range of reasonably possible outcomes.

Preferred Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2020
Temporary Equity Disclosure [Abstract]
Preferred Stock	Preferred Stock Preferred Stock has a liquidation preference of $1,000 per share; is redeemable at our option in cash (or, under certain circumstances, in stock), subject to the applicable redemption premium; is convertible into a variable number of common shares on certain terms and conditions on or after March 31, 2023; and is subject to certain other rights and obligations. Preferred Stock shares earn cumulative dividends at a rate of 10.625% per year, payable quarterly in arrears if declared, and accrue whether or not earned or declared. If a Preferred Stock dividend is declared by the Board of Directors, then it will be paid in cash. Additionally, holders of Preferred Stock participate in any dividends paid on shares of NN’s common stock on an as-converted basis at a fixed conversion rate. If our common stockholders do not approve a proposal at our 2020 annual stockholder meeting to issue common stock in excess of thresholds established by certain Nasdaq stock market rules upon the exercise of Warrants or the conversion or redemption of Preferred Stock, then the annual dividend rate will immediately increase to 11.625% until such time approval is obtained. Preferred Stock is classified as mezzanine equity, between liabilities and stockholders’ equity, because certain features of the Preferred Stock could require redemption of some or all Preferred Stock upon events that are considered not solely within our control, including a leverage ratio threshold and the passage of time. For initial recognition in 2019, the Preferred Stock was recognized at a discounted value, net of issuance costs and allocation to warrants and bifurcated embedded derivatives. The aggregate discount is amortized as a deemed dividend through December 31, 2023, which is the date the holders have a non-contingent conversion option into a variable number of common shares equal to the liquidation preference plus accrued and unpaid dividends. Deemed dividends adjust retained earnings (or in the absence of retained earnings, additional paid-in capital). As of March 31, 2020 , the carrying value of the Preferred Stock shares was $95.7 million which included $3.6 million of accumulated unpaid and deemed dividends. The following table presents the change in the Preferred Stock carrying value during the three months ended March 31, 2020 . Three Months Ended March 31, 2020 Beginning balance $ 93,012 Accrual of in-kind dividends 2,672 Amortization and other (20 ) Ending balance $ 95,664

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Revenue from Contracts with Customers Revenue is recognized when control of the good or service is transferred to the customer either at a point in time or, in limited circumstances, as our services are rendered over time. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or services. Three Months Ended March 31, 2020 Life Mobile Power Intersegment Total United States and Puerto Rico $ 70,362 $ 37,129 $ 38,297 $ (588 ) $ 145,200 China 2,038 7,692 1,157 — 10,887 Mexico 120 4,836 2,143 — 7,099 Brazil — 8,583 130 — 8,713 Germany 5,610 2,150 39 — 7,799 Switzerland 3,032 931 21 — 3,984 Other 2,886 8,563 4,614 — 16,063 Total net sales $ 84,048 $ 69,884 $ 46,401 $ (588 ) $ 199,745 Three Months Ended March 31, 2019 Life Sciences Mobile Solutions Power Solutions Intersegment Sales Eliminations Total United States and Puerto Rico $ 68,343 $ 44,457 $ 41,115 $ (484 ) $ 153,431 China 1,692 9,153 1,838 — 12,683 Mexico 127 5,378 2,709 — 8,214 Brazil — 8,382 69 — 8,451 Germany 8,885 1,406 16 — 10,307 Switzerland 3,265 1,359 16 — 4,640 Other 3,696 7,940 3,894 — 15,530 Total net sales $ 86,008 $ 78,075 $ 49,657 $ (484 ) $ 213,256 Deferred Revenue The following table provides information about contract liabilities from contracts with customers. Deferred Revenue Balance at January 1, 2020 $ 4,172 Balance at March 31, 2020 $ 3,168 Revenue recognized during the three months ended March 31, 2020 , from amounts included in deferred revenue at the beginning of the period for performance obligations satisfied or partially satisfied during the period, was $1.0 million . Transaction Price Allocated to Future Performance Obligations We are required to disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of March 31, 2020 , unless our contracts meet one of the practical expedients. Our contracts met the practical expedient for a performance obligation that is part of a contract that has an original expected duration of one year or less. Sales Concentration We recognized sales from a single customer of $25.6 million , or 13% of consolidated net sales, during the three months ended March 31, 2020 , and $23.3 million , or 11% of consolidated net sales, during the three months ended March 31, 2019 . Revenues from this customer are in our Life Sciences and Power Solutions groups.

Shared-Based Compensation

Shared-Based Compensation	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Shared-Based Compensation	Share-Based Compensation The following table lists the components of share-based compensation expense by type of award. Three Months Ended 2020 2019 Stock options $ 181 $ 192 Restricted stock 892 459 Performance share units 223 222 Share-based compensation expense $ 1,296 $ 873 Stock Options During the three months ended March 31, 2020 , we granted options to purchase 158,700 shares to certain key employees. The weighted average grant date fair value of the options granted during the three months ended March 31, 2020 , was $4.76 per share. The fair value of our options cannot be determined by market value because they are not traded in an open market. Accordingly, we utilized the Black Scholes financial pricing model to estimate the fair value. The following table shows the weighted average assumptions relevant to determining the fair value of stock options granted in 2020 . 2020 Expected term 6 years Risk free interest rate 1.42 % Dividend yield — % Expected volatility 52.80 % The expected term is derived from using the simplified method of determining stock option terms as described under the Staff Accounting Bulletin Topic 14, Share-based payment . The simplified method was used because sufficient historical stock option exercise experience was not available, primarily due to the transformation of the management structure over the past several years. The average risk-free interest rate is derived from the United States Department of Treasury published interest rates of daily yield curves for the same time period as the expected term. The expected dividend yield reflects no expected annual dividends over the expected term because we discontinued dividends in 2019. The expected volatility rate is derived from our actual common stock historical volatility over the same time period as the expected term. The volatility rate is derived by a mathematical formula utilizing daily closing price data. The following table presents stock option activity for the three months ended March 31, 2020 . Number of Options (in thousands) Weighted- Average Exercise Price (per share) Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, 2020 775 $ 13.24 Granted 159 9.44 Exercised — — $ — Forfeited or expired (37 ) 15.10 Outstanding at March 31, 2020 897 $ 12.49 6.0 $ — (1) Exercisable at March 31, 2020 600 $ 13.93 4.4 $ — (1) _______________________________ (1) The aggregate intrinsic value is the sum of intrinsic values for each exercisable individual option grant. The intrinsic value is the amount by which the closing market price of our stock at March 31, 2020 , was greater than the exercise price of any individual option grant. Restricted Stock During the three months ended March 31, 2020 , we granted 460,255 restricted stock awards to non-executive directors, officers and certain other key employees. The shares of restricted stock granted during the three months ended March 31, 2020 , vest pro-rata generally over three years for officers and certain other key employees and over one year for non-executive directors and certain officers. We determined the fair value of the shares awarded by using the closing price of our common stock as of the date of grant. The weighted average grant date value of restricted stock granted in the three months ended March 31, 2020 , was $9.35 per share. Total grant-date fair value of restricted stock that vested in the three months ended March 31, 2020 , was $1.0 million . The following table presents the status of unvested restricted stock awards as of March 31, 2020 , and changes during the three months then ended. Nonvested Restricted Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Unvested at January 1, 2020 222 $ 9.33 Granted 460 9.35 Vested (110 ) 9.28 Forfeited (9 ) 9.44 Unvested at March 31, 2020 563 $ 9.17 Performance Share Units Performance Share Units (“PSUs”) are a form of long-term incentive compensation awarded to executive officers and certain other key employees designed to directly align the interests of employees to the interests of our stockholders, and to create long-term stockholder value. PSUs granted in 2020 were made pursuant to the NN, Inc. 2019 Omnibus Incentive Plan and a Performance Share Unit Agreement (the “2019 Omnibus Agreement”). Some PSUs are based on total shareholder return (“TSR Awards”), and other PSUs are based on return on invested capital (“ROIC Awards”). The TSR Awards vest, if at all, upon our achieving a specified relative total shareholder return, which will be measured against the total shareholder return of the S&P SmallCap 600 Index during specified performance periods as defined in the 2019 Omnibus Agreement. The ROIC Awards vest, if at all, upon our achieving a specified average return on invested capital during the performance periods. Each performance period generally begins on January 1 of the year of grant and ends 36 months later on December 31. We recognize compensation expense over the performance period in which the performance and market conditions are measured. If the PSUs do not vest at the end of the performance periods, then the PSUs will expire automatically. Upon vesting, the PSUs will be settled by the issuance of shares of our common stock, subject to the award recipient’s continued employment. The actual number of shares of common stock to be issued to each award recipient at the end of the performance periods will be interpolated between a threshold and maximum payout amount based on actual performance results. No dividends will be paid on outstanding PSUs during the performance period; however, dividend equivalents will be paid based on the number of shares of common stock that are ultimately earned at the end of the performance periods. With respect to the TSR Awards, a participant will earn 50% of the target number of PSUs for “Threshold Performance,” 100% of the target number of PSUs for “Target Performance,” and 150% of the target number of PSUs for “Maximum Performance.” With respect to the ROIC Awards, a participant will earn 35% of the target number of PSUs for “Threshold Performance,” 100% of the target number of PSUs for “Target Performance,” and 150% of the target number of PSUs for “Maximum Performance. For performance levels falling between the values shown below, the percentages will be determined by interpolation. The following table presents the goals with respect to TSR Awards and ROIC Awards granted in 2020 . TSR Awards: Threshold Performance Target Performance Maximum Performance 2020 grants 35th Percentile 50th Percentile 75th Percentile ROIC Awards: Threshold Performance Target Performance Maximum Performance 2020 grants 4.9 % 5.1 % 5.6 % We estimate the grant date fair value of TSR Awards using the Monte Carlo simulation model, as the total shareholder return metric is considered a market condition under ASC Topic 718, Compensation – stock compensation . The grant date fair value of ROIC Awards is based on the closing price of a share of our common stock on the date of grant. The following table presents the number of PSUs granted and the grant date fair value in the period presented. TSR Awards ROIC Awards Award Year Shares (in thousands) Grant Date Fair Value (per share) Shares (in thousands) Grant Date Fair Value (per share) 2020 139 $ 10.88 157 $ 9.44 We recognize expense for ROIC Awards based on the probable outcome of the associated performance condition. We generally recognize an expense for ROIC Awards based on the Target Performance threshold of 100% because, at the date of grant, the Target Performance is the probable level of performance achievement. The following table presents the status of unvested PSUs as of March 31, 2020 , and changes during the three months then ended. Nonvested TSR Awards Nonvested ROIC Awards Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Nonvested at January 1, 2020 65 $ 13.27 79 $ 11.50 Granted 139 10.88 157 9.44 Forfeited (19 ) 11.43 (21 ) 12.88 Nonvested at March 31, 2020 185 $ 10.53 215 $ 11.04

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income The following table presents the components of accumulated other comprehensive income (“AOCI”). Foreign Currency Translation Interest rate swap Income taxes (2) Total Balance at December 31, 2019 $ (35,159 ) $ (12,234 ) $ 2,839 $ (44,554 ) Other comprehensive income (loss) before reclassifications (14,342 ) (14,599 ) 3,390 (25,551 ) Amounts reclassified from AOCI (1) — 1,370 (318 ) 1,052 Net current-period other comprehensive income (loss) (14,342 ) (13,229 ) 3,072 (24,499 ) Balance at March 31, 2020 $ (49,501 ) $ (25,463 ) $ 5,911 $ (69,053 ) Balance at December 31, 2018 $ (31,314 ) $ — $ — $ (31,314 ) Net current-period other comprehensive income (loss) 1,321 (4,960 ) 1,104 (2,535 ) Balance at March 31, 2019 $ (29,993 ) $ (4,960 ) $ 1,104 $ (33,849 ) _______________________ (1) Amount reflects $1.1 million of settlements on the interest rate swap, net of tax, that are reclassified out of AOCI into interest expense on the Consolidated Statements of Operations and Comprehensive Income (Loss) . (2) Income tax effect of changes in interest rate swap.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income (Loss) Per Common Share In accordance with ASC 260, Earnings Per Share, a company that has participating securities (for example, our Preferred Stock) is required to utilize the two-class method for calculating earnings per share (“EPS”) unless the treasury stock method results in lower EPS. The two-class method is an allocation of earnings between the holders of common stock and a company’s participating securities. Basic EPS is calculated by dividing income or loss attributable to common stockholders by the weighted average number of shares of common stock outstanding. To calculate diluted EPS, basic EPS is further adjusted to include the effect of potentially dilutive stock options, warrants, and Preferred Stock. The following table summarizes the computation of basic and diluted net income (loss) per common share. Three Months Ended 2020 2019 Numerator: Net income (loss) $ (248,191 ) $ (19,518 ) Less: Preferred Stock cumulative dividends and deemed dividends (2,951 ) — Numerator for basic and diluted net income (loss) per common share (1) $ (251,142 ) $ (19,518 ) Denominator: Weighted average common shares outstanding, basic and diluted 42,111 41,972 Per common share net loss: Basic net income (loss) per common share $ (5.96 ) $ (0.47 ) Diluted net income (loss) per common share $ (5.96 ) $ (0.47 ) Cash dividends declared per common share $ — $ 0.07 _______________________________ (1) Preferred Stock does not participate in losses. The following table presents the number of potentially dilutive securities that were excluded from the calculation of diluted net income (loss) per common share because they had an anti-dilutive effect. Three Months Ended 2020 2019 Options 897 676 Warrants 1,500 — Preferred Stock, as-converted 26,275 — 28,672 676 Given the loss from continuing operations in the three months ended March 31, 2020 and 2019 , all options and warrants are considered anti-dilutive and were excluded from the calculation of diluted net income (loss) per share. Stock options excluded from the calculations of diluted net income (loss) per share had a per share exercise price ranging from $7.93 to $25.16 for the three months ended March 31, 2020 , and $8.90 to $25.16 for three months ended March 31, 2019 . Warrants excluded from the calculation of diluted net income (loss) per share for the three months ended March 31, 2020 , had a per share exercise price of $12.00 . Preferred Stock excluded from the calculation of diluted net income (loss) per share for the three months ended March 31, 2020 , was calculated on an as-converted basis. Holders of Preferred Stock will have the right to convert up to 25% of their Preferred Stock into common shares per quarter after December 31, 2023, at a conversion price that equals a 30 -day volume weighted average price per common share. Under certain conditions, holders of Preferred Stock may elect to convert their Preferred Stock into common shares at an earlier date after March 31, 2023, at a conversion price that equals 90% of the volume weighted average market price per common share. The potentially dilutive Preferred Stock in the preceding table presents the more dilutive result of these conversion prices as if the Preferred Stock were converted on March 31, 2020 .

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is an exit price representing the expected amount that an entity would receive to sell an asset or pay to transfer a liability in an orderly transaction with market participants at the measurement date. We followed consistent methods and assumptions to estimate fair values as more fully described in the 2019 Annual Report. Fair value principles prioritize valuation inputs across three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the assumptions used to measure assets and liabilities at fair value. An asset or liability’s classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement. Our financial instruments that are subject to fair value disclosure consist of cash and cash equivalents, accounts receivable, accounts payable, derivatives, and long-term debt. As of March 31, 2020 , the carrying values of these financial instruments approximated fair value. Derivative Financial Instruments Certain features were bifurcated and accounted for separate from the Preferred Stock. The following features are recorded on a combined basis as a single derivative. • Leverage ratio put feature. The Preferred Stock includes a redemption option based on a leverage ratio threshold that provides the preferred holder the option to convert the Preferred Stock to a variable number of shares of common stock at a discount to the then fair value of our common stock. The conversion feature is considered a redemption right at a premium which is not clearly and closely related to the debt host. • Contingent dividends. The feature that allows for the dividend rate to increase to 11.625% in 2020 is not considered clearly and closely related to the debt host. • Dividends withholding. The Preferred Stock bears a feature that could require us to make an effective distribution to purchasers which is indexed to the tax rate of the purchasers. This distribution would be partially offset by an adjustment to the redemption price and/or conversion rate. The dividends withholding feature is not clearly and closely related to the debt host. The following tables show the liabilities measured at fair value for the Preferred Stock derivative above as of March 31, 2020 , and December 31, 2019 . Fair Value Measurements as of March 31, 2020 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ — $ 1,857 Derivative liability - other non-current liabilities — — 617 Total $ — $ — $ 2,474 Fair Value Measurements as of December 31, 2019 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ — $ 60 Derivative liability - other non-current liabilities — — 2,235 Total $ — $ — $ 2,295 The inputs for determining fair value of the Preferred Stock derivative are classified as Level 3 inputs. Level 3 fair value is based on unobservable inputs based on the best information available. These inputs include probability assessments of how long the Preferred Stock will remain outstanding, whether the leverage ratio threshold will be exceeded, and whether approval is obtained from common stockholders for issuance of common stock upon exercise of the Warrants and conversion or redemption of the Preferred Stock. Inputs also include the percentage of Preferred Stock held by non-U.S. resident holders and the applicable tax withholding rates for those holders. The following table presents the change in the Preferred Stock derivative during the three months ended March 31, 2020 . Three Months Ended March 31, 2020 Beginning balance $ 2,295 Change in fair value (1) (60 ) Other 239 Ending balance $ 2,474 _______________________________ (1) Changes in the fair value are recognized in the “ Other (income) expense, net ” line in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) . All of the change in fair value relates to the derivative liability held at March 31, 2020 . Cash Flow Hedge We manage our exposure to fluctuations in interest rates using a mix of fixed and variable rate debt. We have a $700.0 million fixed-rate interest rate swap agreement that changes the LIBOR-based portion of the interest rate on a portion of our variable rate debt to a fixed rate of 2.4575% (the “interest rate swap”) through October 19, 2022 . The interest rate swap effectively mitigates our exposures to the risks and variability of changes in LIBOR. The notional amount of the interest rate swap will decrease over time as presented in the following table. Notional Amount February 12, 2019 - December 30, 2020 $ 700,000 December 31, 2020 - December 30, 2021 466,667 December 31, 2021 - October 19, 2022 233,333 The objective of the interest rate swap is to eliminate the variability of cash flows in interest payments on the first $700.0 million of variable rate debt attributable to changes in benchmark one-month LIBOR interest rates. The hedged risk is the interest rate risk exposure to changes in interest payments, attributable to changes in benchmark one-month LIBOR interest rates over the interest rate swap term. If one-month LIBOR is greater than the minimum percentage under the Senior Secured Term Loan, the changes in cash flows of the interest rate swap are expected to exactly offset changes in cash flows of the variable rate debt. The interest rate swap is designated as a cash flow hedge. As of March 31, 2020 , we reported a $19.6 million loss , net of tax, in accumulated other comprehensive income related to the interest rate swap. The following tables present the liabilities measured at fair value on a recurring basis for the interest rate swap as of March 31, 2020 , and December 31, 2019 . Fair Value Measurements as of March 31, 2020 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liability - other current liabilities $ — $ 13,539 $ — Derivative liability - other non-current liabilities — 11,923 — Total $ — $ 25,462 $ — Fair Value Measurements as of December 31, 2019 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ 5,943 $ — Derivative liability - other non-current liabilities — 6,290 — Total $ — $ 12,233 $ — The inputs for determining fair value of the interest rate swap are classified as Level 2 inputs. Level 2 fair value is based on estimates using standard pricing models. These standard pricing models use inputs which are derived from or corroborated by observable market data such as interest rate yield curves, index forward curves, discount curves, and volatility surfaces. Counterparty to this derivative contract is a highly rated financial institution which we believe carries only a minimal risk of nonperformance. Fixed Rate Debt The fair value of floating-rate debt generally approximates the carrying amount as interest rates are based on short-term maturities. As of March 31, 2020, the aggregate fair value of our Senior Secured Term Loan and Incremental Term Loan is approximately $557.7 million , compared to the net carrying amount of $763.9 million . The fair value of these term loans is based on recently completed market transactions and is primarily classified as Level 2 within the fair value hierarchy. The fair value of our outstanding fixed-rate debt included in the “International lines of credit and other loans” line item within Note 9 to these Notes to Condensed Consolidated Financial Statements was $11.1 million and $9.8 million as of March 31, 2020 and December 31, 2019 , respectively. These fair values represent Level 2 under the three-tier hierarchy described above. The carrying value of this fixed-rate debt was $11.1 million and $9.8 million as of March 31, 2020 and December 31, 2019 , respectively.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event Preferred Share Purchase Rights On April 15, 2020, our Board of Directors authorized and declared a dividend of one preferred share purchase right for each outstanding share of common stock to shareholders of record on April 27, 2020. The rights will become exercisable if a person or group becomes the beneficial owner of 15% or more of our outstanding common stock (including in the form of synthetic ownership through derivative positions). In the event that the rights become exercisable due to the triggering ownership threshold being crossed, each right will entitle its holder to purchase one one-thousandth of a share of Series C Junior Participating Preferred Stock for $31.50 . Rights held by the triggering person or entity will become void and will not be exercisable. The Board of Directors may, rather than permitting the exercise of the rights, exchange each right (other than rights held by the triggering person or entity) for one share of common stock per right, subject to adjustment. The Board of Directors will, prior to the rights becoming exercisable, in general be entitled to redeem the rights for $0.001 per right. The rights expire on March 31, 2021.

Interim Financial Statements (P

Interim Financial Statements (Policies)	3 Months Ended
	Mar. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Nature of Business	Nature of Business NN, Inc. is a global diversified industrial company that combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for the medical, aerospace and defense, electrical, automotive, and general industrial markets. As used in this Quarterly Report on Form 10-Q (this “Quarterly Report”), the terms “NN,” the “Company,” “we,” “our,” or “us” refer to NN, Inc., and its subsidiaries.
Basis of Presentation	Basis of Presentation and Going Concern The accompanying condensed consolidated financial statements have not been audited, except that the Condensed Consolidated Balance Sheet as of December 31, 2019 , was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the “ 2019 Annual Report”), which we filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 16, 2020 . In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary to fairly state our results of operations for the three months ended March 31, 2020 and 2019 ; financial position as of March 31, 2020 , and December 31, 2019 ; and cash flows for the three months ended March 31, 2020 and 2019 , on a basis consistent with our audited consolidated financial statements other than the adoption of new accounting standards (see Accounting Standards Recently Adopted section below). These adjustments are of a normal recurring nature and are, in the opinion of management, necessary to state fairly the Company’s financial position and operating results for the interim periods. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted from the interim financial statements presented in this Quarterly Report. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and accompanying notes included in the 2019 Annual Report. The results for the three months ended March 31, 2020 , are not necessarily indicative of results for the year ending December 31, 2020 , or any other future periods. Except for per share data or as otherwise indicated, all U.S. dollar amounts presented in the tables in these Notes to Condensed Consolidated Financial Statements are in thousands.
Substantial Doubt about Going Concern [Text Block]	In November 2019, we initiated a strategic review to evaluate a broad range of operational, financial, and strategic options to reduce leverage and enhance shareholder value, and we retained external advisors to assist in this effort. The strategic options we are evaluating include further cost savings and cash generation initiatives, more efficient capital deployment, changes to our debt and equity structure to improve financial flexibility and liquidity, and the sale of part or all of NN, among others. As discussed in our 2019 Annual Report, on December 11, 2019, we issued preferred stock for net proceeds of $95.7 million and used a portion of the proceeds to repay amounts due at that time on our Senior Secured Revolver. In December 2019 we amended our Credit Agreement which, in turn, extended the due date of our Senior Secured Revolver to July 20, 2022 , reduced the total capacity under the Senior Secured Revolver to $75.0 million , and extended the due date of our Incremental Term Loan to October 19, 2022 , matching the date of our longer-dated Senior Secured Term Loan. Additionally, as part of this amendment, our debt covenants were amended to establish more restrictive leverage ratios that also become more restrictive over time. Our Consolidated Net Leverage Ratio covenant (the “financial leverage ratio covenant”) is required to be complied with on a quarterly basis at the end of each of our quarterly reporting periods. Our financial leverage ratio covenant is based upon our consolidated net indebtedness at each quarter end and our trailing twelve-month Adjusted EBITDA as defined in our Credit Agreement. In order to maintain compliance with the financial leverage ratio covenant, our operational and financial performance must improve . In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued. We rely on cash flow generated from operations and available borrowings under our Senior Secured Revolver to fund our working capital and other operating and investing needs. Our ability to borrow under the Senior Secured Revolver is based on our continued compliance with our financial leverage ratio covenant, as defined, which becomes more restrictive in the second quarter of 2020 and the first quarter of 2021. The full extent of the effect of the COVID-19 pandemic on our customers, our supply chain and our business cannot be reasonably assessed at this time although we expect our full year 2020 results of operations to be adversely affected. We have developed a plan to mitigate the impact of COVID-19 which includes the implementation of a series of specific and identified cost reductions in both our corporate and business groups, in addition to actions already taken, including further reducing our direct and indirect labor costs and benefits. The impact of COVID-19 on our operating results will depend on future developments, which are highly uncertain and cannot be predicted, including governmental and business reactions to the pandemic. We have made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. If there are differences between these estimates and actual results, our consolidated financial statements may be materially affected. Based on our current and projected use of the Senior Secured Revolver, as well as cash flows expected to be generated from operations and investing activities, we anticipate that we may not be able to maintain compliance with the existing financial leverage ratio covenant for the next twelve months. If we are unable to comply with our financial ratio covenant, then the revolving credit lenders, the Senior Secured Term Loan lenders, and the Incremental Term Loan lenders could take action to cause amounts due under our credit facility to become due and payable unless we are able to amend such covenants or otherwise refinance our debt. Our ability to amend our covenants or refinance our debt is dependent upon several factors, and therefore there can be no assurance that we would be successful in these efforts. If we are unable to access future borrowings or be required to pay amounts due under our credit facilities prior to their normal maturity dates, this would have a material impact to our financial position. We are in negotiations with our lenders to amend the financial leverage ratio covenant; however, there can be no assurance that we will be successful in such efforts. Accordingly, we believe there is substantial doubt about our ability to continue as a going concern for the twelve-month period following the date of this report.
Accounting Standards	Accounting Standards Recently Adopted Financial Instruments - Credit Losses . In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which modifies the measurement of expected credit losses on certain financial instruments and the timing of when such losses are recorded. In November 2019, the SEC issued SAB No. 119, codified in ASC Topic 326, Financial Instruments-Credit Losses, which provides guidance on accounting of credit losses. We adopted ASU 2016-13 on January 1, 2020, using the modified retrospective transition method which resulted in no material adjustment to our financial statements as of January 1, 2020. Fair Value Disclosures. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”) , that modifies fair value disclosure requirements. The new guidance streamlines disclosures of Level 3 fair value measurements. The modified disclosures were effective for us beginning in the first quarter of 2020. ASU 2018-13 changes disclosures only and does not impact our financial condition, results of operations, or cash flows. Internal-Use Software. In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force) (“ASU 2018-15”) , that provides guidance on a customer’s accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor. Under the new guidance, customers apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. We adopted ASU 2018-15 as of January 1, 2020, prospectively. We have had no such costs after the adoption date, and we do not expect the new guidance to have a material impact on our financial statements. Reference Rate Reform. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides temporary optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. Among other things, for all types of hedging relationships, the guidance allows an entity to change the reference rate and other critical terms related to reference rate reform without having to remeasure the value or reassess a previous accounting determination. The amendments in this guidance should be applied on a prospective basis and, for companies with a fiscal year ending December 31, are effective from January 1, 2020, through December 31, 2022. We adopted this guidance effective January 1, 2020. When the transition occurs, we expect to apply this expedient to our existing interest rate swap that references LIBOR, and to any other new transactions that reference LIBOR or another reference rate that is discontinued, through December 31, 2022. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements. Accounting Standards Not Yet Adopted Income Taxes. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, (“ASU 2019-12”) as part of its initiative to reduce complexity in accounting standards. ASU 2019-12 removes certain exceptions and provides simplification to specific tax items to improve consistent application. This standard is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued. Adoption methods vary based on the specific items impacted. We are currently evaluating the impact on our financial statements and related disclosures.

Prior Periods' Financial Stat_2

Prior Periods' Financial Statement Revision (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Schedule of Correction of Misstatements and Revision on Consolidated Statements	The following table presents the effect of the correction of the misstatements and the resulting revision on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) . Three Months Ended March 31, 2019 As Originally Reported Adjustment As Revised Cost of sales (exclusive of depreciation and amortization) $ 161,269 $ 918 $ 162,187 Income (loss) from operations 601 (918 ) (317 ) Loss before (provision) benefit for income taxes and share of net income from joint venture (16,628 ) (918 ) (17,546 ) Net income (loss) (18,600 ) (918 ) (19,518 ) Foreign currency translation gain (loss) 1,262 59 1,321 Comprehensive income (loss) (21,194 ) (859 ) (22,053 ) Basic net income (loss) per share $ (0.44 ) $ (0.03 ) $ (0.47 ) Diluted net income (loss) per share $ (0.44 ) $ (0.03 ) $ (0.47 ) The following table presents the effect of the correction of the misstatements on the Condensed Consolidated Statements of Changes in Stockholders’ Equity . As Originally Reported Adjustment As Revised As of and for the three months ended March 31, 2019 Additional paid-in capital $ 512,274 $ (5,832 ) $ 506,442 Net income (loss) (18,600 ) (918 ) (19,518 ) Accumulated deficit (83,570 ) 5,579 (77,991 ) Foreign currency translation gain (loss) 1,262 59 1,321 Accumulated other comprehensive income (loss) (34,219 ) 370 (33,849 ) Total stockholders' equity 394,909 117 395,026 The following table presents the effect of the correction of the misstatements on the Condensed Consolidated Statements of Cash Flows . Three Months Ended March 31, 2019 As Originally Reported Adjustment As Revised Net income (loss) $ (18,600 ) $ (918 ) $ (19,518 ) Deferred income taxes (4,373 ) (1,331 ) (5,704 ) Changes in operating assets and liabilities, net of acquisitions: Inventories (6,302 ) 677 (5,625 ) Income taxes receivable and payable, net 248 1,331 1,579 Other 4,941 241 5,182

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Information	The following tables present results of operations by reportable segment. Life Sciences Mobile Solutions Power Solutions Corporate and Consolidations Total Three Months Ended March 31, 2020 Net sales $ 84,048 $ 69,884 $ 46,401 $ (588 ) (a) $ 199,745 Goodwill impairment 146,757 — 92,942 — 239,699 Income (loss) from operations (140,979 ) 264 (90,334 ) (14,283 ) $ (245,332 ) Interest expense (17,077 ) Other (1,120 ) Loss before benefit for income taxes and share of net loss from joint venture $ (263,529 ) Three Months Ended March 31, 2019 Net sales $ 86,008 $ 78,075 $ 49,657 $ (484 ) (a) $ 213,256 Income (loss) from operations 3,846 3,189 3,824 (11,176 ) $ (317 ) Interest expense (13,801 ) Other (3,428 ) Loss before provision for income taxes and share of net income from joint venture $ (17,546 ) _______________________________ (a) Includes elimination of intersegment transactions occurring during the ordinary course of business. The following table presents total assets by reportable segment as of March 31, 2020 , and December 31, 2019 . Total Assets March 31, 2020 December 31, 2019 Life Sciences $ 648,603 $ 811,526 Mobile Solutions 362,624 373,256 Power Solutions 214,602 310,545 Corporate and Consolidations 99,324 46,657 Total $ 1,325,153 $ 1,541,984

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories are comprised of the following amounts: March 31, 2020 December 31, 2019 Raw materials $ 36,904 $ 49,135 Work in process 47,054 43,456 Finished goods 34,961 26,131 Total inventories $ 118,919 $ 118,722

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The following table shows changes in the carrying amount of goodwill by reportable segment. Life Sciences Power Solutions Total Balance as of December 31, 2019 $ 344,316 $ 94,779 $ 439,095 Currency impact and other (1,278 ) (1,837 ) (3,115 ) Impairments (146,757 ) (92,942 ) (239,699 ) Balance as of March 31, 2020 $ 196,281 $ — $ 196,281

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Amount of Intangible Assets Net	The following table shows changes in the carrying amount of intangible assets, net by reportable segment. Life Sciences Mobile Solutions Power Solutions Total Balance as of December 31, 2019 $ 211,847 $ 32,416 $ 84,997 $ 329,260 Amortization (7,755 ) (839 ) (2,748 ) (11,342 ) Balance as of March 31, 2020 $ 204,092 $ 31,577 $ 82,249 $ 317,918

Investment in Joint Venture (Ta

Investment in Joint Venture (Tables)	3 Months Ended
	Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Summarized Activity Related to Investment in Joint Venture	The following table shows changes in our investment in the JV. Balance as of December 31, 2019 $ 21,755 Share of earnings (loss) (271 ) Foreign currency translation loss (364 ) Balance as of March 31, 2020 $ 21,120

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Summary of Debt	The following table presents debt balances as of March 31, 2020 , and December 31, 2019 . March 31, 2020 December 31, 2019 Senior Secured Term Loan $ 524,875 $ 526,313 Incremental Term Loan 254,222 257,111 Senior Secured Revolver 60,000 — International lines of credit and other loans 11,140 9,823 Total principal 850,237 793,247 Less-current maturities of long-term debt 20,064 19,160 Principal, net of current portion 830,173 774,087 Less-unamortized debt issuance costs (1) 15,201 16,647 Long-term debt, net of current portion $ 814,972 $ 757,440

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Lease, Cost	The following table contains supplemental cash flow information related to leases. Three Months Ended 2020 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from finance leases $ 120 $ 53 Operating cash flows from operating leases 5,346 5,288 Financing cash flows from finance leases 836 792 Right-of-use assets obtained in exchange for new finance lease liabilities $ 1,404 $ — Right-of-use assets obtained in exchange for new operating lease liabilities $ 13,241 $ 2,836

Preferred Stock (Tables)

Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2020
Temporary Equity Disclosure [Abstract]
Temporary Equity	The following table presents the change in the Preferred Stock carrying value during the three months ended March 31, 2020 . Three Months Ended March 31, 2020 Beginning balance $ 93,012 Accrual of in-kind dividends 2,672 Amortization and other (20 ) Ending balance $ 95,664

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Summary of Revenue from Contracts with Customers	Three Months Ended March 31, 2020 Life Mobile Power Intersegment Total United States and Puerto Rico $ 70,362 $ 37,129 $ 38,297 $ (588 ) $ 145,200 China 2,038 7,692 1,157 — 10,887 Mexico 120 4,836 2,143 — 7,099 Brazil — 8,583 130 — 8,713 Germany 5,610 2,150 39 — 7,799 Switzerland 3,032 931 21 — 3,984 Other 2,886 8,563 4,614 — 16,063 Total net sales $ 84,048 $ 69,884 $ 46,401 $ (588 ) $ 199,745 Three Months Ended March 31, 2019 Life Sciences Mobile Solutions Power Solutions Intersegment Sales Eliminations Total United States and Puerto Rico $ 68,343 $ 44,457 $ 41,115 $ (484 ) $ 153,431 China 1,692 9,153 1,838 — 12,683 Mexico 127 5,378 2,709 — 8,214 Brazil — 8,382 69 — 8,451 Germany 8,885 1,406 16 — 10,307 Switzerland 3,265 1,359 16 — 4,640 Other 3,696 7,940 3,894 — 15,530 Total net sales $ 86,008 $ 78,075 $ 49,657 $ (484 ) $ 213,256
Summary of Contract Liabilities from Contracts with Customers	The following table provides information about contract liabilities from contracts with customers. Deferred Revenue Balance at January 1, 2020 $ 4,172 Balance at March 31, 2020 $ 3,168

Shared-Based Compensation (Tabl

Shared-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Components of Share-Based Compensation Expense by Type of Award	The following table lists the components of share-based compensation expense by type of award. Three Months Ended 2020 2019 Stock options $ 181 $ 192 Restricted stock 892 459 Performance share units 223 222 Share-based compensation expense $ 1,296 $ 873
Weighted Average Assumptions Relevant to Determining the Fair Value at the Dates of Grant and Stock Option Modification	The following table shows the weighted average assumptions relevant to determining the fair value of stock options granted in 2020 . 2020 Expected term 6 years Risk free interest rate 1.42 % Dividend yield — % Expected volatility 52.80 %
Reconciliation of Option Activity	The following table presents stock option activity for the three months ended March 31, 2020 . Number of Options (in thousands) Weighted- Average Exercise Price (per share) Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, 2020 775 $ 13.24 Granted 159 9.44 Exercised — — $ — Forfeited or expired (37 ) 15.10 Outstanding at March 31, 2020 897 $ 12.49 6.0 $ — (1) Exercisable at March 31, 2020 600 $ 13.93 4.4 $ — (1) _______________________________ (1) The aggregate intrinsic value is the sum of intrinsic values for each exercisable individual option grant. The intrinsic value is the amount by which the closing market price of our stock at March 31, 2020 , was greater than the exercise price of any individual option grant.
Reconciliation of Restricted Stock Option Activity	The following table presents the status of unvested restricted stock awards as of March 31, 2020 , and changes during the three months then ended. Nonvested Restricted Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Unvested at January 1, 2020 222 $ 9.33 Granted 460 9.35 Vested (110 ) 9.28 Forfeited (9 ) 9.44 Unvested at March 31, 2020 563 $ 9.17
Schedule of Performance Based Awards Goals with Respect to TSR and ROIC	The following table presents the goals with respect to TSR Awards and ROIC Awards granted in 2020 . TSR Awards: Threshold Performance Target Performance Maximum Performance 2020 grants 35th Percentile 50th Percentile 75th Percentile ROIC Awards: Threshold Performance Target Performance Maximum Performance 2020 grants 4.9 % 5.1 % 5.6 %
Schedule of Number of Awards Granted and Grant Date Fair Value of Each Award in Periods	The following table presents the number of PSUs granted and the grant date fair value in the period presented. TSR Awards ROIC Awards Award Year Shares (in thousands) Grant Date Fair Value (per share) Shares (in thousands) Grant Date Fair Value (per share) 2020 139 $ 10.88 157 $ 9.44
Summary of Status of Unvested PSU Awards	The following table presents the status of unvested PSUs as of March 31, 2020 , and changes during the three months then ended. Nonvested TSR Awards Nonvested ROIC Awards Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Nonvested at January 1, 2020 65 $ 13.27 79 $ 11.50 Granted 139 10.88 157 9.44 Forfeited (19 ) 11.43 (21 ) 12.88 Nonvested at March 31, 2020 185 $ 10.53 215 $ 11.04

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table presents the components of accumulated other comprehensive income (“AOCI”). Foreign Currency Translation Interest rate swap Income taxes (2) Total Balance at December 31, 2019 $ (35,159 ) $ (12,234 ) $ 2,839 $ (44,554 ) Other comprehensive income (loss) before reclassifications (14,342 ) (14,599 ) 3,390 (25,551 ) Amounts reclassified from AOCI (1) — 1,370 (318 ) 1,052 Net current-period other comprehensive income (loss) (14,342 ) (13,229 ) 3,072 (24,499 ) Balance at March 31, 2020 $ (49,501 ) $ (25,463 ) $ 5,911 $ (69,053 ) Balance at December 31, 2018 $ (31,314 ) $ — $ — $ (31,314 ) Net current-period other comprehensive income (loss) 1,321 (4,960 ) 1,104 (2,535 ) Balance at March 31, 2019 $ (29,993 ) $ (4,960 ) $ 1,104 $ (33,849 ) _______________________ (1) Amount reflects $1.1 million of settlements on the interest rate swap, net of tax, that are reclassified out of AOCI into interest expense on the Consolidated Statements of Operations and Comprehensive Income (Loss) . (2) Income tax effect of changes in interest rate swap.

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended 2020 2019 Options 897 676 Warrants 1,500 — Preferred Stock, as-converted 26,275 — 28,672 676
Summary of Net Income (Loss) Per Share	Three Months Ended 2020 2019 Numerator: Net income (loss) $ (248,191 ) $ (19,518 ) Less: Preferred Stock cumulative dividends and deemed dividends (2,951 ) — Numerator for basic and diluted net income (loss) per common share (1) $ (251,142 ) $ (19,518 ) Denominator: Weighted average common shares outstanding, basic and diluted 42,111 41,972 Per common share net loss: Basic net income (loss) per common share $ (5.96 ) $ (0.47 ) Diluted net income (loss) per common share $ (5.96 ) $ (0.47 ) Cash dividends declared per common share $ — $ 0.07

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Derivative Instruments	The following table presents the change in the Preferred Stock derivative during the three months ended March 31, 2020 . Three Months Ended March 31, 2020 Beginning balance $ 2,295 Change in fair value (1) (60 ) Other 239 Ending balance $ 2,474 _______________________________ (1) Changes in the fair value are recognized in the “ Other (income) expense, net ” line in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) . All of the change in fair value relates to the derivative liability held at March 31, 2020 . The following tables show the liabilities measured at fair value for the Preferred Stock derivative above as of March 31, 2020 , and December 31, 2019 . Fair Value Measurements as of March 31, 2020 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ — $ 1,857 Derivative liability - other non-current liabilities — — 617 Total $ — $ — $ 2,474 Fair Value Measurements as of December 31, 2019 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ — $ 60 Derivative liability - other non-current liabilities — — 2,235 Total $ — $ — $ 2,295
Schedule of Notional Amounts of Outstanding Derivative Positions	The notional amount of the interest rate swap will decrease over time as presented in the following table. Notional Amount February 12, 2019 - December 30, 2020 $ 700,000 December 31, 2020 - December 30, 2021 466,667 December 31, 2021 - October 19, 2022 233,333
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables present the liabilities measured at fair value on a recurring basis for the interest rate swap as of March 31, 2020 , and December 31, 2019 . Fair Value Measurements as of March 31, 2020 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liability - other current liabilities $ — $ 13,539 $ — Derivative liability - other non-current liabilities — 11,923 — Total $ — $ 25,462 $ — Fair Value Measurements as of December 31, 2019 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ 5,943 $ — Derivative liability - other non-current liabilities — 6,290 — Total $ — $ 12,233 $ —

Interim Financial Statements -

Interim Financial Statements - Additional Information (Detail) - USD ($) $ in Millions	Dec. 11, 2019	Mar. 31, 2020
Senior Secured Revolving Facility
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Principal available		$ 75
Series B Convertible Preferred Stock
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Proceeds from issuance of preferred stock and preference stock	$ 95.7

Prior Periods Financial Stateme

Prior Periods Financial Statement Revision - Schedule of Correction of Misstatements and Revision on Consolidated Statement of Operations and Comprehensive Income (Loss) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of sales (exclusive of depreciation and amortization shown separately below)	$ 152,241	$ 162,187
Income (loss) from operations	(245,332)	(317)
Loss before benefit (provision) for income taxes and share of net income (loss) from joint venture	(263,529)	(17,546)
Net income (loss)	(248,191)	(19,518)
Foreign currency translation gain (loss)	(14,342)	1,321
Comprehensive income (loss)	$ (272,690)	$ (22,053)
Basic - net loss per share (in dollars per share)	$ (5.96)	$ (0.47)
Diluted - net loss per share (in dollars per share)	$ (5.96)	$ (0.47)
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of sales (exclusive of depreciation and amortization shown separately below)		$ 161,269
Income (loss) from operations		601
Loss before benefit (provision) for income taxes and share of net income (loss) from joint venture		(16,628)
Net income (loss)		(18,600)
Foreign currency translation gain (loss)		1,262
Comprehensive income (loss)		$ (21,194)
Basic - net loss per share (in dollars per share)		$ (0.44)
Diluted - net loss per share (in dollars per share)		$ (0.44)
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of sales (exclusive of depreciation and amortization shown separately below)		$ 918
Income (loss) from operations		(918)
Loss before benefit (provision) for income taxes and share of net income (loss) from joint venture		(918)
Net income (loss)		(918)
Foreign currency translation gain (loss)		59
Comprehensive income (loss)		$ (859)
Basic - net loss per share (in dollars per share)		$ (0.03)
Diluted - net loss per share (in dollars per share)		$ (0.03)
Continuing Operations As Revised
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of sales (exclusive of depreciation and amortization shown separately below)		$ 162,187
Income (loss) from operations		(317)
Loss before benefit (provision) for income taxes and share of net income (loss) from joint venture		(17,546)
Net income (loss)		(19,518)
Foreign currency translation gain (loss)		1,321
Comprehensive income (loss)		$ (22,053)
Basic - net loss per share (in dollars per share)		$ (0.47)
Diluted - net loss per share (in dollars per share)		$ (0.47)

Prior Periods Financial State_2

Prior Periods Financial Statement Revision - Schedule of Corrections of Misstatements and Revision on Consolidated Statements of Changes in Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Additional paid-in capital	$ 499,925		$ 501,615
Net loss	(248,191)	$ (19,518)
Accumulated deficit	(353,474)		(105,283)
Foreign currency translation gain (loss)	(14,342)	1,321
Accumulated other comprehensive loss	(69,053)		(44,554)
Total stockholders’ equity	$ 78,902	395,026	$ 353,277	$ 419,271
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Additional paid-in capital		512,274
Net loss		(18,600)
Accumulated deficit		(83,570)
Foreign currency translation gain (loss)		1,262
Accumulated other comprehensive loss		(34,219)
Total stockholders’ equity		394,909
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Additional paid-in capital		(5,832)
Net loss		(918)
Accumulated deficit		5,579
Foreign currency translation gain (loss)		59
Accumulated other comprehensive loss		370
Total stockholders’ equity		117
Continuing Operations As Revised
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Additional paid-in capital		506,442
Net loss		(19,518)
Accumulated deficit		(77,991)
Foreign currency translation gain (loss)		1,321
Accumulated other comprehensive loss		(33,849)
Total stockholders’ equity		$ 395,026

Prior Periods' Financial Stat_3

Prior Periods' Financial Statement Revision Prior Periods' Financial Statement Revision - Schedule of Corrections of Misstatements and Revision on Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ (248,191)	$ (19,518)
Inventories	(2,507)	(5,625)
Income taxes receivable and payable, net	$ (12,676)	1,579
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss		(18,600)
Deferred income taxes		(4,373)
Inventories		(6,302)
Income taxes receivable and payable, net		248
Other		4,941
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss		(918)
Deferred income taxes		(1,331)
Inventories		677
Income taxes receivable and payable, net		1,331
Other		241
Continuing Operations As Revised
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss		(19,518)
Deferred income taxes		(5,704)
Inventories		(5,625)
Income taxes receivable and payable, net		1,579
Other		$ 5,182

Segment Information (Detail)

Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Segment Reporting Information [Line Items]
Net sales	$ 199,745	$ 213,256
Goodwill impairment	239,699	0
Income (loss) from operations	(245,332)	(317)
Interest expense	(17,077)	(13,801)
Other	(1,120)	(3,428)
Loss before benefit (provision) for income taxes and share of net income (loss) from joint venture	(263,529)	(17,546)
Total assets	1,325,153		$ 1,541,984
Life Sciences
Segment Reporting Information [Line Items]
Goodwill impairment	(146,757)
Total assets	648,603		811,526
Mobile Solutions
Segment Reporting Information [Line Items]
Total assets	362,624		373,256
Power Solutions
Segment Reporting Information [Line Items]
Goodwill impairment	(92,942)
Total assets	214,602		310,545
Corporate and Consolidations
Segment Reporting Information [Line Items]
Total assets	99,324		$ 46,657
Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Net sales	84,048	86,008
Goodwill impairment	146,757
Income (loss) from operations	(140,979)	3,846
Operating Segments | Mobile Solutions
Segment Reporting Information [Line Items]
Net sales	69,884	78,075
Goodwill impairment	0
Income (loss) from operations	264	3,189
Operating Segments | Power Solutions
Segment Reporting Information [Line Items]
Net sales	46,401	49,657
Goodwill impairment	92,942
Income (loss) from operations	(90,334)	3,824
Corporate and Eliminations | Corporate and Consolidations
Segment Reporting Information [Line Items]
Net sales	(588)	(484)
Goodwill impairment	0
Income (loss) from operations	$ (14,283)	$ (11,176)

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 36,904	$ 49,135
Work in process	47,054	43,456
Finished goods	34,961	26,131
Total inventories	$ 118,919	$ 118,722

Goodwill - Changes in Carrying

Goodwill - Changes in Carrying Amount of Goodwill (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Goodwill [Roll Forward]
Beginning Balance	$ 439,095
Currency impact and other	(3,115)
Goodwill, impairment loss	239,699	$ 0
Ending Balance	196,281
Power Solutions
Goodwill [Roll Forward]
Beginning Balance	94,779
Currency impact and other	(1,837)
Goodwill, impairment loss	(92,942)
Ending Balance	0
Life Sciences
Goodwill [Roll Forward]
Beginning Balance	344,316
Currency impact and other	(1,278)
Goodwill, impairment loss	(146,757)
Ending Balance	$ 196,281

Goodwill - Additional Informati

Goodwill - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Goodwill [Line Items]
Goodwill	$ 196,281		$ 439,095
Goodwill, impairment loss	239,699	$ 0
Intangible assets, net	317,918		329,260
Mobile Solutions
Goodwill [Line Items]
Goodwill	0
Intangible assets, net	31,577		32,416
Life Sciences
Goodwill [Line Items]
Goodwill	196,281		344,316
Goodwill, impairment loss	(146,757)
Intangible assets, net	204,092		211,847
Power Solutions
Goodwill [Line Items]
Goodwill	0		94,779
Goodwill, impairment loss	(92,942)
Intangible assets, net	$ 82,249		$ 84,997

Intangible Assets, Net - Summar

Intangible Assets, Net - Summary of Carrying Amount of Intangible Assets by Segment (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	$ 329,260
Amortization	(11,342)
Ending balance	317,918
Mobile Solutions
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	32,416
Amortization	(839)
Ending balance	31,577
Power Solutions
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	84,997
Amortization	(2,748)
Ending balance	82,249
Life Sciences
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	211,847
Amortization	(7,755)
Ending balance	$ 204,092

Investment in Joint Venture - A

Investment in Joint Venture - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Net sales	$ 199,745,000	$ 213,256,000
Joint Venture
Schedule of Equity Method Investments [Line Items]
Impairment charge	$ 0		$ 16,600,000
Wuxi Weifu Autocam Precision Machinery Company, Ltd.
Schedule of Equity Method Investments [Line Items]
Investment in joint venture	49.00%
Product | Joint Venture
Schedule of Equity Method Investments [Line Items]
Net sales	$ 100,000	$ 100,000

Investment in Joint Venture - S

Investment in Joint Venture - Summarized Activity Related to Investment in Joint Venture (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Equity Method Investments [Roll Forward]
Beginning Balance	$ 21,755
Our share of cumulative earnings	(271)	$ 269
Ending Balance	21,120
Joint Venture
Equity Method Investments [Roll Forward]
Beginning Balance	21,755
Our share of cumulative earnings	(271)
Foreign currency translation gain	(364)
Ending Balance	$ 21,120

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Effective tax rate from continuing operations	5.90%	(12.80%)
Change in tax rate, income tax expense (benefit)		$ 6

Debt - Summary of Debt (Detail)

Debt - Summary of Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Debt Instrument [Line Items]
International lines of credit and other loans	$ 11,100		$ 9,800
Total	850,237	$ 793,247
Less current maturities of long-term debt	20,064	19,160
Principal, net of current portion	830,173	774,087
Less unamortized debt issuance costs	15,201	16,647
Long-term debt, net of current portion	814,972	757,440
Senior Secured Term Loan B
Debt Instrument [Line Items]
Senior debt	524,875	526,313
Incremental Term Loan
Debt Instrument [Line Items]
Senior debt	254,222	257,111
Senior Secured Revolving Facility
Debt Instrument [Line Items]
Senior debt	60,000	0
Foreign Line of Credit
Debt Instrument [Line Items]
International lines of credit and other loans	$ 11,140
Foreign Line of Credit | Chinese
Debt Instrument [Line Items]
International lines of credit and other loans		$ 9,823

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Debt Instrument [Line Items]
Capitalized interest costs	$ 300	$ 600
Remaining borrowing capacity	3,400
Senior Secured Term Loan B
Debt Instrument [Line Items]
Borrowings	$ 545,000
Interest rate during period	6.74%
Senior debt	$ 524,875		$ 526,313
Senior Secured Term Loan B | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin	5.75%
Senior Secured Term Loan B | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Interest rate	0.75%
Incremental Term Loan
Debt Instrument [Line Items]
Borrowings	$ 300,000
Interest rate during period	6.74%
Senior debt	$ 254,222		257,111
Incremental Term Loan | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin	5.75%
Senior Secured Revolving Facility
Debt Instrument [Line Items]
Debt issuance costs, line of credit arrangements, net	$ 2,700		3,000
Interest rate during period	4.96%
Unused capacity, commitment fee percentage	0.50%
Principal available	$ 75,000
Senior debt	$ 60,000		$ 0
Senior Secured Revolving Facility | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin	4.00%
Senior Secured Revolving Facility | Prime Rate
Debt Instrument [Line Items]
Applicable margin	3.00%
Interest Rate Swap
Debt Instrument [Line Items]
Derivative, notional amount	$ 700,000
Derivative, fixed interest rate	2.4575%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from finance leases	$ 120	$ 53
Operating cash flows from operating leases	5,346	5,288
Financing cash flows from finance leases	836	792
Right-of-use assets obtained in exchange for new finance lease liabilities	1,404	0
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 13,241	$ 2,836

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	1 Months Ended
	Mar. 31, 2020USD ($)
Lessee, Lease, Description [Line Items]
Lessee, operating lease, lease not yet commenced, amount	$ 27.5
Lessee, operating lease, lease not yet commenced, term of contract	15 years
Operating lease, reduction of base rent payments over lease term	$ 1.3
Increase (decrease) in operating lease, right-of-use asset	8.1
Increase (decrease) in operating lease, liability, noncurrent	10.5
Increase (decrease) in operating lease, liability, current	0.6
Increase (decrease) in change between operating lease right-of-use assets and operating lease, liabilities	3
Gain (loss) on termination of lease	4.4
Impairment charge on termination of lease	$ 2.9

Restructuring and Integration -

Restructuring and Integration - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring and integration expense, net	$ 0	$ (12)
Pay period for accrued restructuring and integration costs	1 year 1 month 25 days
Restructuring and related cost, expected cost remaining	$ 300
Severance and Other Employee Costs
Restructuring Cost and Reserve [Line Items]
Payments for restructuring	(90)
Restructuring and integration expense, net	$ 400

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) shares in Millions	Nov. 01, 2019	Mar. 31, 2020	Dec. 31, 2019
Contingencies And Commitments [Line Items]
Amount accrued for estimation of loss		$ 0
Stock Issued During Period, Shares, New Issues	14.4
Minimum
Contingencies And Commitments [Line Items]
Possible loss estimated			$ 0
Maximum
Contingencies And Commitments [Line Items]
Possible loss estimated			$ 6,000,000

Preferred Stock - Additional In

Preferred Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Temporary Equity [Line Items]
Series B convertible preferred stock	$ 95,664	$ 93,012
Accrual of in-kind dividends	$ 3,600
Series B Convertible Preferred Stock
Temporary Equity [Line Items]
Temporary equity, liquidation preference per share	$ 1,000
Temporary equity, dividend rate, percentage	10.625%
Temporary equity, increase in dividend rate, percentage	11.625%
Series B convertible preferred stock	$ 95,664	$ 93,012
Accrual of in-kind dividends	$ 2,672

Preferred Stock - Carrying Valu

Preferred Stock - Carrying Value Roll Forward (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Temporary Equity [Line Items]
Beginning balance	$ 93,012
Accrual of in-kind dividends	3,600
Ending balance	95,664
Series B Convertible Preferred Stock
Temporary Equity [Line Items]
Beginning balance	93,012
Accrual of in-kind dividends	2,672
Amortization and other	(20)
Ending balance	$ 95,664

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Summary of Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue, Major Customer [Line Items]
Net sales	$ 199,745	$ 213,256
Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	(588)	(484)
United States
Revenue, Major Customer [Line Items]
Net sales	145,200	153,431
United States | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	(588)	(484)
Chinese
Revenue, Major Customer [Line Items]
Net sales	10,887	12,683
Chinese | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Mexico
Revenue, Major Customer [Line Items]
Net sales	7,099	8,214
Mexico | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Brazil
Revenue, Major Customer [Line Items]
Net sales	8,713	8,451
Brazil | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Germany
Revenue, Major Customer [Line Items]
Net sales	7,799	10,307
Germany | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Switzerland
Revenue, Major Customer [Line Items]
Net sales	3,984	4,640
Switzerland | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Other Country
Revenue, Major Customer [Line Items]
Net sales	16,063	15,530
Other Country | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Life Sciences | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	84,048	86,008
Life Sciences | United States | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	70,362	68,343
Life Sciences | Chinese | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	2,038	1,692
Life Sciences | Mexico | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	120	127
Life Sciences | Brazil | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	0	0
Life Sciences | Germany | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	5,610	8,885
Life Sciences | Switzerland | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	3,032	3,265
Life Sciences | Other Country | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	2,886	3,696
Mobile Solutions | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	69,884	78,075
Mobile Solutions | United States | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	37,129	44,457
Mobile Solutions | Chinese | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	7,692	9,153
Mobile Solutions | Mexico | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	4,836	5,378
Mobile Solutions | Brazil | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	8,583	8,382
Mobile Solutions | Germany | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	2,150	1,406
Mobile Solutions | Switzerland | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	931	1,359
Mobile Solutions | Other Country | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	8,563	7,940
Power Solutions | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	46,401	49,657
Power Solutions | United States | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	38,297	41,115
Power Solutions | Chinese | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,157	1,838
Power Solutions | Mexico | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	2,143	2,709
Power Solutions | Brazil | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	130	69
Power Solutions | Germany | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	39	16
Power Solutions | Switzerland | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	21	16
Power Solutions | Other Country | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	$ 4,614	$ 3,894

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Contract Liabilities from Contracts with Customers (Detail) $ in Thousands	Mar. 31, 2020USD ($)
Contract with Customer, Liability [Abstract]
Deferred revenue, beginning balance	$ 4,172
Deferred revenue, ending balance	$ 3,168

Revenue from Contracts with C_5

Revenue from Contracts with Customers Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue, Major Customer [Line Items]
Amounts included in deferred revenue for performance obligations satisfied or partially satisfied	$ 1
Major Customer
Revenue, Major Customer [Line Items]
Revenues	$ 25.6	$ 23.3
Major Customer | Customer Concentration Risk | Sales Revenue, Net
Revenue, Major Customer [Line Items]
Concentration risk, percentage	13.00%	11.00%

Shared-Based Compensation - Com

Shared-Based Compensation - Components of Share-Based Compensation Expense by Type of Award (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 1,296	$ 873
Stock Option Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	181	192
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	892	459
Performance Based Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 223	$ 222

Shared-Based Compensation - Add

Shared-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)	158,700
Weighted average grant date fair value of the options granted (in dollars per share) | $ / shares	$ 4.76
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	460,255
Fair value assumptions, exercise price (in dollars per share) | $ / shares	$ 9.35
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $	$ 1
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	139,000
Percentage of shares issuable based on threshold performance	50.00%
Percentage of shares issuable based on target performance	100.00%
Percentage of shares issuable based on maximum performance	150.00%
Threshold performance, percentage	35.00%
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	157,000
Percentage of shares issuable based on threshold performance	35.00%
Percentage of shares issuable based on target performance	100.00%
Percentage of shares issuable based on maximum performance	150.00%
Threshold performance, percentage	4.90%
Officers and Key Employees | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	3 years
Non-executive Directors | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	1 year

Shared-Based Compensation - Wei

Shared-Based Compensation - Weighted Average Assumptions Relevant to Determining the Fair Value at the Dates of Grant and Stock Option Modification (Detail) - Stock Option Awards	3 Months Ended
	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years
Risk free interest rate	1.42%
Dividend yield	0.00%
Expected volatility	52.80%

Shared-Based Compensation - Rec

Shared-Based Compensation - Reconciliation of Option Activity (Detail) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Number of Options (in thousands)
Beginning balance (in shares) | shares	775,000
Granted (in shares) | shares	158,700
Exercised (in shares) | shares	0
Forfeitures or expired (in shares) | shares	(37,000)
Ending balance (in shares) | shares	897,000
Options exercisable (in shares) | shares	600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning balance (in dollars per share) | $ / shares	$ 13.24
Granted (in dollars per share) | $ / shares	9.44
Exercised (in dollars per share) | $ / shares	0
Forfeitures (in dollars per share) | $ / shares	15.10
Ending balance (in dollars per share) | $ / shares	12.49
Options exercisable (in dollars per share) | $ / shares	$ 13.93
Weighted-average remaining contractual term, outstanding	6 years
Weighted- average remaining contractual term, options exercisable	4 years 5 months
Aggregate intrinsic value, exercised | $	$ 0
Aggregate intrinsic value, outstanding | $	0
Aggregate intrinsic value, options exercisable | $	$ 0

Shared-Based Compensation - R_2

Shared-Based Compensation - Reconciliation of Restricted Stock Option Activity (Detail)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Restricted Stock
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) | shares	222,000
Nonvested restricted shares, granted (in shares) | shares	460,255
Nonvested restricted shares, vested (in shares) | shares	(110,000)
Nonvested restricted shares, forfeited (in shares) | shares	(9,000)
Nonvested restricted shares, ending balance (in shares) | shares	563,000
Weighted average grant-date fair value, beginning balance (in dollara per share) | $ / shares	$ 9.33
Weighted average grant-date fair value, granted (in dollars per share) | $ / shares	9.35
Weighted average grant-date fair value, vested (in dollars per share) | $ / shares	9.28
Weighted average grant-date fair value, forfeited (in dollars per share) | $ / shares	9.44
Weighted average grant-date fair value, ending balance (in dollars per share) | $ / shares	$ 9.17
TSR Awards
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) | shares	65,000
Nonvested restricted shares, granted (in shares) | shares	139,000
Nonvested restricted shares, forfeited (in shares) | shares	(19,000)
Nonvested restricted shares, ending balance (in shares) | shares	185,000
Weighted average grant-date fair value, beginning balance (in dollara per share) | $ / shares	$ 13.27
Weighted average grant-date fair value, granted (in dollars per share) | $ / shares	10.88
Weighted average grant-date fair value, forfeited (in dollars per share) | $ / shares	11.43
Weighted average grant-date fair value, ending balance (in dollars per share) | $ / shares	$ 10.53
ROIC Awards
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) | shares	79,000
Nonvested restricted shares, granted (in shares) | shares	157,000
Nonvested restricted shares, forfeited (in shares) | shares	(21,000)
Nonvested restricted shares, ending balance (in shares) | shares	215,000
Weighted average grant-date fair value, beginning balance (in dollara per share) | $ / shares	$ 11.50
Weighted average grant-date fair value, granted (in dollars per share) | $ / shares	9.44
Weighted average grant-date fair value, forfeited (in dollars per share) | $ / shares	12.88
Weighted average grant-date fair value, ending balance (in dollars per share) | $ / shares	$ 11.04

Shared-Based Compensation - Sch

Shared-Based Compensation - Schedule of Performance Based Awards Goals with Respect to TSR and ROIC (Detail)	3 Months Ended
	Mar. 31, 2020
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold performance, percentage	35.00%
Target performance, percentage	50.00%
Maximum performance, percentage	75.00%
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold performance, percentage	4.90%
Target performance, percentage	5.10%
Maximum performance, percentage	5.60%

Shared-Based Compensation - Sum

Shared-Based Compensation - Summary of Number of Awards Granted and Grand Date Fair Value (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date Fair Value (in dollars per share)	$ 9.44
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number | shares	139
Grant Date Fair Value (in dollars per share)	$ 10.88
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number | shares	157
Grant Date Fair Value (in dollars per share)	$ 9.44

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Beginning balance	$ 2,839	$ 0
OCI before reclassifications, tax	3,390
Amounts reclassified from AOCI, tax	(318)
Other comprehensive income (loss), tax	3,072	1,104
Other comprehensive income (loss)	(24,499)	(2,535)
Ending balance	5,911	1,104
Accumulated Foreign Currency Adjustment Attributable to Parent
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Beginning balance	(35,159)	(31,314)
OCI before reclassifications and tax	(14,342)
Amounts reclassified from AOCI, before tax	0
Other comprehensive income (loss), before tax	(14,342)	1,321
Ending balance	(49,501)	(29,993)
AOCI Attributable to Parent
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Beginning balance	(44,554)	(31,314)
OCI before reclassifications, net of tax	(25,551)
Amounts reclassified from AOCI, net of tax	(1,052)
Other comprehensive income (loss)	(24,499)	(2,535)
Ending balance	(69,053)	(33,849)
Interest Rate Swap | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Beginning balance	(12,234)	0
OCI before reclassifications and tax	(14,599)
Amounts reclassified from AOCI, before tax	1,370
Other comprehensive income (loss), before tax	(13,229)	(4,960)
Ending balance	$ (25,463)	$ (4,960)

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Summary of Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net loss	$ (248,191)	$ (19,518)
Less: Preferred Stock cumulative dividends and deemed dividends	(2,951)	0
Numerator for basic and diluted net income (loss) per common share	$ (251,142)	$ (19,518)
Weighted average common shares outstanding, basic and diluted	42,111	41,972
Basic - net loss per share (in dollars per share)	$ (5.96)	$ (0.47)
Diluted - net loss per share (in dollars per share)	(5.96)	(0.47)
Cash dividends declared per share (in dollars per share)	$ 0	$ 0.07

Net Income (Loss) Per Share Net

Net Income (Loss) Per Share Net Income (Loss) Per Share - Antidilutive Securities Excluded from Computation (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	28,672	676
Stock Option Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	897	676
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,500	0
Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	26,275	0

Net Income (Loss) Per Share - A

Net Income (Loss) Per Share - Additional Information (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, minimum price range	$ 7.93	$ 8.90
Anti dilutive securities excluded from computation of earnings per share, maximum price range	25.16	$ 25.16
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 12
Preferred stock, conversion limit	25.00%
Preferred stock, period of volume weighted average price per common share	30 days
Preferred stock, conversion percentage of volume weighted average market price, percent	90.00%

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements - Liabilities Measure at Fair Value for Preferred Stock (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	$ 0	$ 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Noncurrent Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	0	0
Significant Other Observable Inputs (Level 2) | Other Current Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	0	0
Significant Other Observable Inputs (Level 2) | Other Noncurrent Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	2,474	2,295
Significant Unobservable Inputs (Level 3) | Other Current Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	1,857	60
Significant Unobservable Inputs (Level 3) | Other Noncurrent Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	$ 617	$ 2,235

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying value	$ 850,237	$ 793,247
Line of credit, fair value disclosure	11,100	$ 9,800
International lines of credit and other loans	11,100		$ 9,800
Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	$ 700,000
Derivative, fixed interest rate	2.4575%
Less: reclassification adjustment for (gains) losses included in net income, net of tax	$ (19,600)
Secured Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying value	763,900
Significant Other Observable Inputs (Level 2) | Secured Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	$ 557,700
Series B Convertible Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Temporary equity, increase in dividend rate, percentage	11.625%

Fair Value Measurements - Notio

Fair Value Measurements - Notional Amounts of the Interest Rate Swap (Details)	Mar. 31, 2020USD ($)
February 12, 2019 - December 30, 2020
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative, notional amount	$ 700,000
December 31, 2020 - December 30, 2021
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative, notional amount	466,667
December 31, 2021 - October 19, 2022
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative, notional amount	$ 233,333

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	$ 0	$ 0
Derivative liability - other non-current liabilities	0	0
Total	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	13,539	5,943
Derivative liability - other non-current liabilities	11,923	6,290
Total	25,462	12,233
Significant Unobservable Inputs (Level 3)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	0	0
Derivative liability - other non-current liabilities	0	0
Total	$ 0	$ 0

Fair Value Measurements Fair _2

Fair Value Measurements Fair Value Measurements - Roll Forward of Preferred Stock Derivative (Details) - Significant Unobservable Inputs (Level 3) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 2,295
Change in fair value	(60)
Other	239
Ending balance	$ 2,474

Subsequent Events (Details)

Subsequent Events (Details) - $ / shares	Apr. 15, 2020	Mar. 31, 2020
Subsequent Event [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 12
Subsequent Event | Board of Directors | Common Stock
Subsequent Event [Line Items]
Purchase right, number of shares called by each right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 0.001
Subsequent Event | Series C Junior Participating Preferred Stock
Subsequent Event [Line Items]
Purchase right issued per share of common stock (in shares)	1
Purchase right, number of shares called by each right (in shares)	0.001
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 31.50
Subsequent Event | Minimum | Series C Junior Participating Preferred Stock
Subsequent Event [Line Items]
Purchase right, beneficial owner threshold, percentage	15.00%

Uncategorized Items - nnbr-2020

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 18,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 18,000